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Development of Micron-Scale Hydrogel Materials for the 
Treatment and Management of Heart Failure 
 
Long Van Le 
 
Abstract 
 Ischemic heart disease is the leading cause of death worldwide, accounting for over 16% 
of deaths each year. While we have succeeded in lowering mortality rates through improved care 
in the acute setting, treating the chronic morbidities that affect the surviving patient population 
remains a significant challenge. This has led to rising healthcare costs and increased mortality 
due to chronic heart failure. In this work, we describe novel micro- and nano-fabricated 
technologies to manage and treat heart failure. First, we describe the development and 
application of hyaluronic acid-based polymeric microstructures, termed “microrods”, to attenuate 
the development of scar tissue following a myocardial infarction and prevent pathological 
myocardial remodeling. In vitro studies demonstrate the influence of these HA microrods on 
fibroblasts and cardiomyocyte phenotype, down-regulating key fibrotic indicators. When 
injected into the infarct zone of adult Sprague-Dawley rats after induction of a myocardial 
infarction, HA microrods improved cardiac function and preserved the structure of the 
myocardium as shown by echocardiography and histology, respectively. We then explore novel 
functionalization of these microrod materials through surface conjugation, drug loading or 
nanoparticle loading to confer additional therapeutic mechanisms. Lastly, we demonstrate the 
synthesis and optimization of optical nanoparticle sensors to detect oxygen, glucose and lactate. 
These sensors are incorporated into tissue-integrating hydrogel scaffolds and can be implanted 
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subcutaneously for continuous sensing to track the progression of heart disease. In summary, we 
developed several innovative therapeutic strategies utilizing micro- and nanoengineered 
materials that can be used for comprehensive management and treatment of heart failure.  
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Chapter 1 – Introduction 
 
1.1 Myocardial infarction and the progression of cardiac fibrosis 
Within the past few decades, advancements in biomedical research and improvements in 
emergency response systems have reduced mortality rates in the acute setting of myocardial 
infarction (MI)1. By comparison, the resulting chronic complications of heart failure that develop 
in the wake of tissue trauma remain a substantial challenge2–5. Here, we review the 
pathophysiology of myocardial infarction and heart failure, as well as current strategies to 
mitigate this poor prognosis. 
A myocardial infarction is an acute medical emergency in which the heart is cut off from 
blood flow, resulting in severe cardiac ischemia. The lack of nutrient and oxygen supply to the 
heart results in substantial cell necrosis in the affected area that initiates an inflammatory cascade 
by release of intracellular signaling components6,7. During this inflammatory response, which 
typically occurs within 1-5 days of MI, a range of immune cells, including macrophages, 
monocytes and neutrophils are recruited to the injury site, where they actively produce cytokines 
and proteolytic enzymes8–10. This leads to degradation of the cardiac extracellular matrix (ECM) 
and subsequent release of latent signaling factors. 
Cardiac fibroblasts, previously thought to be a senescent cell type, responds to these 
events and transform into a more active myofibroblast phenotype, producing high amounts of 
matrix proteins, including collagen I and III, to restore the mechanical properties of the 
myocardium11–14. However, unlike activated fibroblasts present in other areas of the body, 
cardiac myofibroblasts do not readily revert back to their inactive state, resulting in continuous 
deposition of scar tissue15–17. This progressive tissue stiffening leads to additional stress on the 
heart and reduces cardiac output. In response, several compensatory mechanisms are activated in 
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attempts to increase blood output and meet the metabolic demands of the body, which can be 
categorized into two primary pathways. First, activation of the sympathetic system attempts to 
increase cardiac output by increasing heart rate and myocardial contractility4,18. Second, the 
renin-angiotensin-aldosterone system (RAAS) is activated to induce vasoconstriction and 
retention of sodium and water to increase blood volume4,19. While able to increase cardiovascular 
output in the short-term, prolonged activation of these compensatory mechanisms is 
counterproductive and places excessive strain on the heart. These myocardial stresses induce 
further pathological tissue remodeling and exacerbates the progression towards heart failure.  
 
1.2 Acellular therapies for the treatment and management of heart failure 
 Several therapeutic interventions have been used to mitigate the progression of chronic 
heart failure, including pharmacological agents, cardiac patches and bulk polymer injections. 
Pharmacological agents, such as angiotensin converting enzyme (ACE) inhibitor and beta-
adrenergic blocking agents (beta blockers) act on the sympathetic and RAAS systems to reduce 
the work load on the heart either directly or by vasodilation to reduce blood pressure3,19–25. This 
reduction of mechanical stress limits left ventricular wall thinning and infarct expansion, slowing 
down the progression of heart failure. 
Ventricular restraint devices that entirely enclose either the left ventricle or both 
ventricles have also been studied for the treatment of heart failure26–28. These restraints target 
infarct expansion by directly reducing myocardial wall stress throughout the ventricle and 
thereby limiting ECM remodeling and scar tissue formation both within the infarct and 
throughout the non-infarcted myocardium. The most extensively studied of these devices are the 
Acorn CorCap Cardiac Support Device and the Paracor HeartNet, both which have undergone 
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clinical trial testing28–37. The Acorn CorCap device is a flexible, polyethylene-terephthalate mesh 
that is wrapped over both ventricles to limit diastolic volume to prevent LV expansion and 
increase cardiac output. In animal studies, the CorCap device was shown to not only preserve, 
but also reverse the changes in cardiac structure and function due to aberrant remodeling38,39. 
The Paracor HeartNet limits LV dilatation in a similar fashion, but is able to exert force onto 
both ventricles throughout the cardiac cycle due to use of an elastic Nitinol mesh material37,40.  
Despite exciting results in preclinical animal studies, the therapeutic efficacy of these 
devices was less clear in clinical trials. In a randomized study of 300 patients, the CorCap device 
demonstrated significant reduction in LV end diastolic volume (LVEDV) and LV end systolic 
volume (LVESV), but no differences in LV ejection fraction (LVEF) or survival advantage at 12 
months compared to controls29–32. Similarly, the Paracor HeartNet device showed significant 
improvements in LV end diastolic dimension (LVEDD), LVEDV and LVESV in a 
nonrandomized trial of 21 patients, but failed to show improvements in survival or mVO2 in a 
larger randomized study of 217 patients, casting doubt onto the efficacy of these restraint 
devices34,37. Since then, there have been no updates on the investigation of these materials for the 
treatment of heart failure. It is also important to note that the application of these materials is 
limited to a subset of patients with HF. The progression of HF must be severe enough to 
necessitate surgical procedures, while not advanced enough such that the restraint devices are 
unable to provide any functional benefits. 
These limitations are partially addressed by the use of injectable materials, namely 
polymeric hydrogels, to increase LV wall thickness and moderate mechanical load to reduce wall 
stress and pathological LV remodeling. These materials can be injected into the myocardium via 
catheter injection through less invasive procedures, eliminating the need for surgical operations. 
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A host of synthetic and natural materials have been studied and extensively reviewed41–45. 
Synthetic materials, such as poly(N-isopropylacrylamide) and poly(ethylene glycol), offer the 
benefit of being well characterized and easily engineered to impart desired functionalities, such 
as sheer-thinning properties, controlled degradation, or temperature and pH sensitivity. By 
comparison, natural materials exhibit greater biocompatibility and degradation kinetics and are 
often able to recapitulate the biophysical and chemical properties of the native ECM. Hyaluronic 
acid, for example, has been widely used for this application because it is bioresorbable and has 
critical roles in wound healing46–55. Recently, there has been significant interest in using 
decellularized ECM for tissue engineering applications. These materials preserve binding motifs 
and signaling components present in healthy tissue to recruit progenitor cells or improve cell 
survival and promote endogenous repair mechanisms56–59. While many of these materials, both 
synthetic and natural, have shown great promise in preclinical studies, only a few have 
proceeded to clinical trials thus far.  
The PRESERVATION-1 trial investigated the effectiveness of an alginate hydrogel (IK-
5001) for prevention of ventricular remodeling in 303 patients60–62. Interestingly, there were no 
significant improvements in cardiac function compared to control groups, in contrast to the 
therapeutic benefits observed in a preclinical porcine ischemia/reperfusion model. Another 
alginate-based material, Algisyl-LVR, was also investigated in clinical trials63–65. This material 
consists of two components: a Na+ alginate solution and a Ca2+ alginate solution that are mixed 
immediately before use. This hydrogel is delivered the alginate hydrogel via 10-15 injections 
during a coronary artery bypass grafting and showed improvements in LVEDV, LVESV and 
LVEF in all patients in a preliminary study63,64. A follow-up study, AUGMENT-HF, consisting 
of 78 patients with advanced heart failure investigated the therapeutic benefits of Algisyl-LVR 
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injections compared to standard medical therapy alone. After 12 month follow-up, mean peak 
VO2 and mean 6 minute walk distance increased in patients injected with Algisyl-LVR while 
decreases in these metrics was observed in control patients65,66. Additionally, there were 
improvements in EF shortly after injection, but these improvements were not sustained in the 
long-term and did not significantly differ from the control treatment group. 
 
1.3 Cell-based therapies for cardiac tissue regeneration 
In recent years, development of stem cell-based therapies has been at the forefront of 
preclinical and clinical research in cardiac regeneration and heart failure67–71. Initial studies 
focused on promoting cardiac repair by delivery of stem or progenitor cell populations into the 
infarct area, which would then differentiate into functional cardiomyocytes. A large number of 
clinical trials have since been conducted to study the efficacy of a wide range of cell types, 
including cardiac stem cells, mesenchymal stem cells and iPSCs, but have failed to conclusively 
demonstrate long-term clinical efficacy71–74. This can be attributed to the heterogeneity in study 
design, such as variation in cell types and origin, dosage, delivery mechanism and patient disease 
state. Additionally, there is incomplete understanding of the mechanism by which transplanted 
stem cells contribute to cardiac regeneration, further obstructing the development of a clinically 
viable stem cell-based therapy. For example, one hypothesis is that stem cells promote cardiac 
regeneration by release of paracrine factors to stimulate proliferation and differentiation of 
endogenous cell types, leading many researchers to focus on designing cell-free approaches that 
act through a similar mode of action75–81. It is therefore crucial for investigators to backtrack and 
precisely standardize study design prior to conducting additional clinical trials, which have so far 
failed to define a clear and effective clinical approach. 
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Cardiac patches that incorporate the mechanical elements of an LV restraint device with 
the regenerative capacity of stem cells have been investigated for replacement of diseased or 
damaged tissue following myocardial injury26,82. Typically, these patches involve the use of a 
biomaterial scaffold for enhanced cell delivery to infarct area, although their utilization as an 
acellular therapy has also recently been observed. Scaffolds have been fabricated out of a variety 
of inert and bioactive materials, such as silk, poly-L-lactic acid, or collage, and impregnated with 
cells before being sutured onto the infarct area82. Recently, Stoppel et al developed cardiac 
ECM-silk graft materials that combine the native signaling properties of cardiac ECM with the 
tunable mechanical properties of silk to enhance cell infiltration, viability, and functional activity 
83. A major advantage of pre-formed scaffolds is that their structure and geometry can be 
precisely designed via microfabrication, soft lithography, and electrospinning approaches to 
support cell infiltration and engraftment. Through this, researchers have been able to grow 
cardiomyocytes in aligned layers within the patch for synchronous beating post-implant, a key 
requirement that is often unmet when injecting cells alone. One enduring challenge of this 
approach, however, is the inability to generate patches with adequate thickness due to diffusion 
limitations – thick scaffolds must integrate with the host tissue and rapidly vascularize to deliver 
adequate amounts of oxygen and nutrients to the implanted cells. As very metabolically 
demanding cells, ischemia for even 30 minutes can result in significant cell death and reduction 
in graft efficacy84. Acellular patches that deliver pharmacological or biological agents to 
stimulate paracrine signaling pathways and harness intrinsic healing mechanisms may provide a 
simpler alternative for tissue repair. 
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1.4 Microtopographical approaches to modulate cell behavior for cardiac repair 
Cells in the heart are continuously subjected to mechanical forces and are equipped with 
an abundance of cellular machinery to detect and respond to these forces85–87. While this has 
been recognized since the early 1980s, mechanical stimuli have only recently been utilized for 
tissue engineering applications. For example, Gwak et al demonstrated that cyclic mechanical 
stretch can influence differentiation and activity of cardiomyocytes in vitro88. This strategy has 
been widely used to generate sheets of cardiomyocytes for the previously mentioned cardiac 
patches. There is therefore great potential in utilizing local mechanical stimuli to locally 
reprogram native cells in the infarcted myocardium and harness intrinsic regenerative pathways 
for cardiac regeneration. 
 As described in this chapter, there is significant degradation of the cardiac extracellular 
matrix following a myocardial infarction, resulting in altered mechanical stiffness and disruption 
of cell-cell and cell-ECM interactions12,89. These dramatic changes are thought to induce 
phenotypic changes of cardiomyocytes and cardiac fibroblasts that lead to overexpression of 
ECM proteins and formation of a stiff myocardial scar. To address this, microengineered 
materials have been developed to attenuate the fibrotic response by providing anchors to cells in 
this weakened 3D microenvironment and decrease stress-induced mechanotransductive 
pathways. Boateng et al first observed that when grown on polyethylene glycol dimethacrylate 
(PEGDMA) micropegs, cardiac fibroblasts form intimate attachments to nearby structures and 
exhibit reduced proliferation90. Similarly, Allen et al used a lamination approach to produce 
polypropylene microfibers of varying aspect ratio and demonstrated reduced fibrotic 
encapsulation when implanted in mice91. For therapeutic applications in cardiovascular repair, 
adaptation of these technologies towards an injectable therapy is required. Ayala et al utilized 
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free PEGDMA microstructures in 3D culture to attenuate fibroblast proliferation and inhibit 
expression of key myofibroblast markers implicated in cardiac fibrosis92. These PEGDMA 
microstructures are reproducibly fabricated on silicon wafers via a scalable photolithography 
approach and can be easily removed from the wafer and stored until use. PEGDMA microrod 
treatment mitigated loss of cardiac function in a rat model of MI93. These studies collectively 
highlight the potential of microtopography and mechanotransduction for the treatment of cardiac 
fibrosis and heart failure. There are, however, several limitations that must be addressed before 
this strategy can be used clinically. Firstly, biocompatibility and degradation of these materials 
have yet to be rigorously determined and may present complications for long-term use. Second, 
optimal dosing has not been determined, although higher doses of microstructures have been 
correlated with improved cardiac function in a rat model of MI. Finally, this microstructural 
approach has only been tested with an acute MI model for attenuation of fibrosis and it is unclear 
whether these beneficial effects will also be observed in a chronic model of heart failure. Despite 
these concerns, this therapeutic approach is still in its infancy and there are exciting opportunities 
for optimization including, but not limited to, investigation of alternative synthetic and natural 
materials, codelivery with pharmacological or cellular therapeutics, and development of a precise 
and reliable delivery method. 
 
1.5 Towards development of a comprehensive treatment for heart failure 
 The development of a comprehensive treatment of heart failure remains an elusive 
challenge. An ideal treatment strategy would involve attenuation of cardiac fibrosis and LV 
remodeling, as well as regeneration of cardiac tissue to restore functional output. The ability to 
monitor disease progression or functional improvements is also critical, as it would enable 
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patients and healthcare providers to quickly respond to adverse developments in disease state. 
Finally, all of these interventions should be easily administered by noninvasive routes and be 
applicable to a wide range of patients with variable disease states. 
 Here, we describe the use of microengineered hydrogel materials to address these 
challenges. In chapter 2, we develop and fully characterize a hyaluronic acid-based microrod 
material for manipulation of fibroblast and cardiomyocyte behavior in vitro. In chapter 3, 
investigate the application of these materials for the treatment of cardiac fibrosis using fibroblast 
cell lines and a rat model of ischemia/reperfusion, respectively. Chapter 4 expands on the 
versatility of these microscale materials by incorporation of additional components to impart 
additional functionalities, such as remote manipulation, release of therapeutics and surface 
functionalization. Lastly, the development of hydrogel scaffold-nanosensor composite materials 
for the continuous detection of blood metabolites is described in chapter 5. 
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Chapter 2 – Development of Hyaluronic Acid Microstructures for Micromechanical 
Interaction with Cardiac Fibroblasts and Myocytes 
 
2.1. Introduction 
Repairing cardiac tissue after myocardial infarction (MI) is one of the most challenging 
goals in tissue engineering. Following ischemic injury, significant matrix remodeling and the 
formation of avascular scar tissue significantly impairs cell engraftment and survival in the 
damaged myocardium5,7,11,12. This aberrant response limits the efficacy of endogenous repair 
mechanisms and cell replacement therapies, necessitating the development of strategies that 
reduce pathological scarring to create a suitable microenvironment for healthy tissue 
regeneration. Such advancements would enhance our clinical capabilities in treating the chronic 
complications of MI in a growing patient population progressing towards heart failure. 
Within the past several decades, mechanical forces have gained significant appreciation 
as a potent mechanism for altering cellular activity94–100. Mechanically sensitive cells, such as 
fibroblasts, cardiomyocytes and endothelial cells, are able to detect environmental forces through 
ion channels, integrins and other surface receptors85,86,97,101–103. These forces are transduced into 
intracellular signals that elicit transcriptional changes leading to altered cellular phenotype.  Our 
lab has previously investigated the use of polymeric microrods and microfibers to mitigate the 
fibrotic response through these biophysical pathways91–93. These features locally alter the 
microenvironment by providing anchors for fibroblast attachment, resulting in significant 
changes in proliferation, myofibroblast differentiation and ECM protein expression. While 
promising, the use of bioinert, nondegradable materials for presents several complications for 
long-term use in the clinical setting. There is also great potential in using bioactive materials to 
deliver biochemical cues in addition to mechanical stimuli for additional therapeutic benefits. 
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Hyaluronic acid (HA) is a naturally derived polysaccharide that can be adapted for this 
microtopography-based approach to cardiac tissue regeneration. It is widely distributed in the 
body at high molecular weights and is degraded into small fragments by hyaluronidases and 
oxidative hydrolysis46,47,104,105. These two forms of HA have distinct effects on a range of 
biological processes, including angiogenesis and inflammation46–49,104–108. While HMWHA has 
anti-angiogenic and anti-inflammatory effects, short fragments stimulate proliferation and 
migration to promote angiogenesis. Accordingly, many HA-based scaffolds have been developed 
within the past decade to exploit these properties for wound healing applications52–55. 
 In this chapter, we present the development of hyaluronic acid-based microrods for the 
treatment of chronic cardiac fibrosis. These HA-based microrods can be reproducibly fabricated 
using standard photolithographic techniques and are demonstrated to be biodegradable, promote 
cell growth and attenuate the myofibroblast phenotype.  
 
2.2 Materials and Methods 
2.2.1 Materials 
 Sodium hyaluronate (100kDa) was purchased from Lifecore Biomedical (Chaska, MN). 
Glycidyl methacrylate, triethylamine, 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone 
(HMPP), Hyaluronidase (type I-S) from bovine testes, sodium tetraborate decahydrate, sulfuric 
acid, and carbazole were purchased from Sigma-Aldrich (St. Louis, MO). 4'-
(aminomethyl)fluorescein and sulfo-SANPAH were purchased from ThermoFisher Scientific 
(Waltham, MA). Collagenase type II was purchased from Worthington Biochemical (Lakewood, 
NJ). Acrylamide, n,n'-methylenebisacrylamide (bis) solution, ammonium persulfate, and 
tetraethylmethylenediamine were purchased from Bio-Rad (Hercules, CA). 
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2.2.2 Synthesis of hyaluronic acid methacrylate 
Hyaluronic acid methacrylate was synthesized based on a method published by Bencherif 
et al109. Briefly, sodium hyaluronate (100 kDa) was dissolved in a solution of 1:1 deionized 
water:dimethylformamide at 3.75 mg/mL. A 100-fold molar excess of glycidyl methacrylate and 
35-fold molar excess of triethylamine was then added. The reaction was allowed to proceed for 
24 hours at room temperature and away from light. Hyaluronic acid and hyaluronic acid 
methacrylate were recovered by precipitation in an excess of isopropanol. The precipitate was 
then pelleted by centrifugation at 700 x g for 5 minutes and dissolved in water. The resulting 
solution was dialyzed against water for 48 hours with three changes and lyophilized for 3 days at 
-40 °C and 65 mtorr to yield a dry powder. Degree of methacrylation was determined by 1H-
NMR in D2O using a Bruker Avance III HD 400 NMR. 
 
2.2.3 Characterization of hyaluronic acid methacrylate stiffness 
Crosslinked hyaluronic acid methacrylate hydrogels were fabricated in a range of 
concentration for mechanical testing. Briefly, HMPP was dissolved in water at a 0.5% w/v 
concentration. The resulting solution was used to dissolve HAMA at 25, 50, 75 and 100 mg/mL. 
Once fully dissolved, the solution was centrifuged at max speed for 5 minutes to remove 
impurities. The precursor solution was then injected into a mold comprising of a 0.8 mm Teflon 
spacer sandwiched between two glass slides and exposed to 365 nm UV light for 5 minutes. The 
resulting crosslinked hydrogel was retrieved and allowed to swell further in water. The stiffness 
of these hydrogels was determined by atomic force microscopy using a MFP3D-BIO inverted 
optical AFM (Asylum Research) mounted on a Nikon TE2000-U inverted fluorescent 
microscope. For these measurements, a gold deposited silicon nitride cantilever (k = 0.09 N/m) 
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with a pyramidal tip was used. 10 measurements were made for each hydrogel at 3 different 
locations. The average of these 30 measurements was used for each replicate. Cantilevers were 
calibrated using a thermal oscillation method prior to each session. 
 
2.2.4 HA microrod fabrication 
Solutions of hyaluronic acid methacrylate were prepared as described above. A 15 µm 
thick layer of this solution was deposited onto a piranha cleaned silicon wafer and exposed 
through a photomask to a 365 nm UV light source using a Karl Suss Mask Aligner to crosslink 
the hyaluronic acid methacrylate in rod shapes (15 µm × 100 µm). The microrods were then 
gently scraped off the surface of the wafer using a cell scraper and collected into water, where 
uncrosslinked regions of hyaluronic acid methacrylate would fully dissolve. The microrods were 
passed through a 150 µm mesh filter to remove large particles and washed thoroughly by 
centrifugation. The microrods are sterilized with 70% ethanol and resuspended in saline or cell 
culture medium prior to use. Microrods were imaged using differential interference contrast 
(DIC). To visualize 3D geometry, HA microrods were labeled with 4'-(aminomethyl)fluorescein 
(Thermofisher, Waltham, MA) through EDC/NHS coupling and imaged using confocal 
microscopy. 
 
2.2.5 Degradation of crosslinked hyaluronic acid methacrylate 
Crosslinked hyaluronic acid methacrylate hydrogels were degraded at 37 °C in 100, 10 or 
0 U/mL hyaluronidase in phosphate buffered saline (PBS). The supernatant for each hydrogel 
was collected and replaced with fresh hyaluronidase solution every 48 hours. For each time 
point, the amount of uronic acid was measured using a carbazole-based reaction110.  Briefly, 200 
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μl of 24 mM sodium tetraborate decahydrate dissolved in concentrated sulfuric acid was added to 
50 ul of each sample and heated to 100 °C for 10 minutes. 50 μl of 0.125% carbazole in absolute 
ethanol was then added to each sample and heated to 100 °C for 15 minutes. 200 ul of each 
solution was analyzed in a plate reader at 530 nm. Known concentrations of 100 kDa HA were 
used as a standard. Following the last time point, all remaining hydrogels were placed in 
concentrated sulfuric acid and assayed to determine the total amount of HA remaining. 
For HA microrods, degradation was conducted by incubating the microrods in 100 U/mL, 
10 U/mL and 0 U/mL hyaluronidase at 37 °C. The microrods were pelleted by centrifugation at 
maximum speed for 5 minutes. The supernatant was collected and replaced with fresh buffer 
solution. Uronic acid was quantified as described above. 
 
2.2.6 Neonatal rat ventricular fibroblast and myocyte culture 
Primary heart cultures were obtained from neonatal rats according to Institutional and 
National Institutes of Health guidelines. Hearts were removed from 1- to 2-day-old Sprague-
Dawley rats and cells isolated using collagenase type II, per previously established protocol111. 
Fibroblasts, which had been separated from myocytes during isolation, were cultured an 
additional 2 days before detaching cells with trypsin and seeding in new dishes for experiments. 
 
2.2.7 Interaction of cardiac fibroblasts and myocytes with HA microrods 
Fibroblasts and myocytes were cultured with HA microrods on a 10kPa polyacrylamide 
substrate to visualize interactions under physiological stiffness. Briefly, 40% unpolymerized 
acrylamide and 2% bis solution were diluted in water at final concentrations of 5% acrylamide 
and 0.3% Bis. Ammonium persulfate and tetraethylmethylenediamine were added to initiate 
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polymerization. A total of 10 uL of the pre-polymer solution was then added to glass bottom 
dishes and covered with a circular coverslip. The solution was allowed to polymerize for 10 
minutes, then coverslips were gently removed, leaving behind a flat, circular substrate. Dishes 
were washed three times in DI water for 10 min at a time to remove unpolymerized acrylamide. 
These surfaces were then treated twice by drying sulfo-SANPAH in HEPES (50 mM, pH 8.5) on 
each surface for 60 minutes at 57 °C. A UV exposure box with a 365 nm bulb was used to link 
the sulfo-SANPAH to the substrate. The substrate was then washed 3x and then coated with 
HEPES containing fibronectin (10 µg/mL) at 37 °C for at least 2 hours before UV-sterilizing in 
water for 20 minutes. The water was then aspirated under sterile conditions and HA microrods 
were added. Fibroblasts alone, myocytes alone, or a combination of both fibroblasts and 
myocytes were plated at desired density. 
 
2.2.8 Image analysis 
A Zeiss LSM 710 confocal microscope at the University of Illinois at Chicago was used 
for fluorescence imaging of myocyte and fibroblast interactions with HA microrods after 24 
hours in vitro. Single-plane and Z-stack images were obtained using a 63x Zeiss objective. Cells 
were fixed in 10% formalin and probed for focal adhesions using a primary antibody for paxillin 
[ab32084] (Abcam, Cambridge, MA) at 1:250 dilution. The antibody was incubated overnight, 
then counterstained with secondary antibody (A21207, Thermofisher, Waltham, MA), 
rhodamine phalloidin (R415, Thermofisher, Waltham, MA), and DAPI (H-1200, Vector 
Laboratories, Burlingame, CA). Visualization of fibronectin bound to microrods was conducted 
by incubating HA microrods for 2 hours at 37 °C in 10 μg/mL of fibronectin in PBS, or in PBS 
alone as a control. Fibronectin was eliminated by three cycles of centrifugation and resuspension 
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in PBS. Microrods were incubated with a fibronectin antibody (ab26245, Abcam, Cambridge, 
MA) at a 1:1000 dilution for 1 hour at 37 ºC before centrifugation and resuspension in PBS three 
times; then, microrods were incubated with fluorescently-labeled secondary antibody (A21202, 
Thermofisher, Waltham, MA) at a 1:400 dilution for 1 hour at room temperature before imaging 
in a fluorescence microscope. 
 
2.2.9 Statistical analysis 
All values for continuous variables are listed as the mean ± one standard deviation, unless 
otherwise indicated. In vitro and in vivo analysis was performed using a one-way analysis of 
variance (ANOVA), followed by multiple comparison by Holm-Sidak correction to identify 
differences between groups. 
 
2.3 Results 
2.3.1 Fabrication of hyaluronic acid-based microrods in a range of stiffness 
In order to fabricate hyaluronic acid microrods through photolithography, we adapted 
published protocols to functionalize HA with UV-sensitive methacrylate groups (Figure 2.1A)109. 
1H NMR spectroscopy confirmed the substitution of hydroxyls with methacrylate groups, 
showing methacrylate peaks at 6.1 and 5.65 ppm (Figure 2.1B). To determine the degree of 
substitution, we compared the integrations of the methacrylate peaks with the acetamide peak in 
HA at 1.85 ppm and found that we were able to reproducibly synthesize hyaluronic acid 
methacrylate (HAMA) with 41 ± 3% substitution. 
A time course study was conducted on this reaction over 5 days to ensure completeness 
of reaction (Figure 2.1C). At each time point, a reaction sample was taken, purified and analyzed 
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by 1H-NMR. Our results indicate that the reaction goes to completion after 24 hours, likely due 
to the reactivity of the glycidyl group to epoxide ring opening.  
We have previously found that microrods must have an elastic modulus of at least 20 kPa 
in order to significantly affect cell behavior92. To determine the concentration of HAMA 
necessary to yield microrods of desired stiffness, we measured the elastic modulus of hydrogel 
slabs fabricated with a range of HAMA concentrations. Atomic force microscopy measurements 
showed that the modulus of these hydrogels increase exponentially from 1kPa to 160kPa with 
increasing HAMA concentration (Figure 2.2). 
Photolithography was used to reproducibly create 15 x 15 x 100 µm HA microrods in a 
range of stiffness (Figure 2.3A). The dimensions of the microrods were controlled by the 
photomask while the stiffness was controlled by total HAMA concentration in the precursor 
solution. Brightfield microscopy confirmed uniform fabrication of HA microrods across the 
wafer (Figure 2.3B). Since HA is very hygroscopic, the fabricated HA microrods exhibit 
moderate swelling in solution. The dimensions of fully swollen HA microrods were confirmed 
by labeling HA microrods with a fluorescein label and imaging with confocal microscopy 
(Figure 2.3C). 
 
2.3.2 Degradation kinetics of hyaluronic acid microrods 
We conducted degradation studies on slabs of HAMA to understand the behavior of 
HAMA breakdown. Slabs of HAMA at varying concentration were incubated in buffer 
containing 100 U/mL, 10 U/mL and 0 U/mL of hyaluronidase. Samples were taken every two 
days and the degradation buffer was replenished. A carbazole-based detection assay was used to 
quantify the amount of HA released by degradation110. In samples incubated with 100 U/mL of 
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hyaluronidase, 25 mg/mL and 50 mg/mL HAMA slabs degraded quickly and were completely 
disintegrated at 2 and 4 days, respectively (Figure 2.4A). As HAMA concentration increased, 
degradation was much slower, as seen in the 75 mg/mL and 100 mg/mL slabs, which did not 
completely degrade until after 3 weeks. This can be attributed to the increasing number of 
crosslinks that can be formed at higher HAMA concentrations, as observed with the nonlinear 
increases in elastic modulus with increasing HAMA. This results in a tighter mesh network in 
which only HAMA fragments on the surface are accessible to hyaluronidase. This is consistent 
with our observation that 75 and 100 mg/mL HAMA slabs became smaller in size, but 
maintained their mechanical integrity (Figure 2.4B). By contrast, 25 and 50 mg/mL HAMA slabs 
became softer over a short period of time and then fully dissolved. 
To confirm this, we compared degradation of 100 mg/mL HAMA slabs in 100 U/mL and 
10 U/mL hyaluronidase. Not surprisingly, we found that slabs in 10 U/mL hyaluronidase 
degraded much slower than those in 100 U/mL hyaluronidase (Figure 2.4C-D). However, at two 
weeks, the rate of degradation for both groups became nearly identical. This suggests that there 
is an initial phase where there are many accessible HAMA fragments and degradation is 
dependent on hyaluronidase concentration; and that there is a second phase where the rate 
limiting factor is the number of accessible HAMA fragments on the surface of the slab. We 
propose that hydrolysis of the crosslinks, which occurs much slower than enzyme mediated chain 
scission, loosens the polymer network and is the limiting step in this phase of degradation. This 
suggests that geometry may be a major factor in determining degradation time, so we proceeded 
to repeat these studies with HA microrods. 
HA microrods were made using 75 mg/mL and 100 mg/mL of HAMA and incubated in 
buffer containing hyaluronidase, as described above. Samples were taken every two days and 
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measured using the carbazole assay. Interestingly, we find that there is no significant difference 
between the degradation of 75 mg/mL and 100 mg/mL HA microrods (Figure 2.5A). The surface 
area to volume ratio of HA microrods is much greater than HAMA slabs, exposing more HAMA 
fragments to enzyme for degradation. As a result, the degradation of the HA microrods is also 
much faster than the HAMA polymer slabs. The 75 mg/mL and 100 mg/mL HA microrods were 
50% degraded by 1 and 2 days, respectively, compared to their HAMA slab counterparts which 
were 50% degraded by 3 and 6 days. Differential interference contrast (DIC) imaging showed 
that these microrods degrade by surface erosion (Figure 2.5B). 
We conducted additional degradation studies with physiological concentrations of 
hyaluronidase at lower pH to simulate inflamed tissue. HA microrods were made using 50 
mg/mL HAMA and incubated at pH 5.7 in 0.26 U/mL hyaluronidase. Our data show that these 
microrods were approximately 80% degraded after 7 days (Figure 2.6). 
 
2.3.3 Influence of hyaluronic acid microrods on cardiac fibroblasts and myocytes in vitro 
We grew fibroblasts with HA microrods to evaluate the effect of HA microrods on 
fibroblast behavior in vitro. Primary neonatal rat ventricular fibroblasts (NRVFs) adhered to and 
spread on the HA microrods, often conforming to and enveloping the entirety of the rod (Figure 
2.7). Paxillin staining showed that the NRVFs formed distinct focal adhesions to the edges of the 
microrods, potentially initiating several mechanotransduction pathways. These results were 
consistent in fibroblast/myocyte co-culture as well. The fibroblasts appeared to have a stronger 
affinity for the rods, stretching and spreading across the microrods while the myocytes formed 
tight attachments to the edges (Figure 2.8A). While a key binding partner to HA, CD44 was not 
found to be localized to the HA microrod and was instead present at high levels over the entire 
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fibroblast membrane (Figure 2.8B). We found that HA microrods readily bind to fibronectin, 
providing surface ligands for focal adhesion formation (Figure 2.9). Together, these data suggest 
that integrin-binding is a major mechanism for cell attachment to the microrods. 
  
2.4 Discussion 
In this work, we developed a novel materials-based strategy that combines the wound 
healing properties of hyaluronic acid with microtopographical cues to modulate the cellular 
phenotype. We fabricated discrete microrods using a photocrosslinkable derivative of HA, 
characterized their mechanical properties and enzyme-mediated degradation, and examined their 
interaction with cardiac fibroblasts and myocytes in vitro. 
There have been significant advances within the past few decades on the use of 
micromechanical cues for modulating cell behavior. Microgrooves have been widely used to 
confine the growth of fibroblasts and cardiomyocytes into aligned rows and influence 
proliferation and differentiation112,113. Microposts in 2D and microstructures in 3D have been 
demonstrated to affect cellular phenotype by maintaining cellular tension via anchorage and has 
been used to attenuate the fibrotic response90–93,113,114. While applications of these materials have 
seen success, there remain opportunities to modify these materials for additional biological 
functionalities. 
 We utilized a glycidyl methacrylate synthesis strategy to functionalize the HA backbone 
with UV-curable pendant groups. This reaction mechanism was selected because precise control 
of reaction pH was not required, unlike syntheses utilizing methacrylic anhydride109,115–117. This 
provided an easy and reproducible way for us to synthesize HA methacrylate. There has been, 
however, much debate on the mechanism of this reaction. The attachment can occur either by 
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substitution of the carboxylic acid with the methacrylic acid group, or by epoxide ring opening 
via the 6’ hydroxyl109,118. Recent studies have shown that under basic conditions, glycidyl 
methacrylate reacts with the 6’ hydroxyl by both epoxide ring opening and transesterification, 
with the epoxide ring opening being the dominant mechanism119. As epoxides are highly 
reactive, we hypothesized that the reaction is complete after 24 hours, confirming this by a 
reaction time course (Figure 2.1C). This contrasts with previous protocols that necessitate 5-10 
days of reaction time to get significant degrees of substitution109. Despite this, we were able to 
get consistent substitution efficiencies of between 40-45%. This efficiency varies quite 
drastically in the literature even when similar protocols are used. This can be attributed to the 
integration of NMR peaks during analysis. The reference peak used is generally of the acetamide 
protons, which has significant overlap with other peaks. This can result in highly variable 
calculation of substitution efficiency, depending on how the integration is done. Further, 
differences in purification protocol can cause differences in both yield and purity. While not 
shown here, we observed that changing the dialysis membrane from a 3k cutoff to a 10k cutoff 
reduced our yield by nearly 50%, possibly due to the polydispersity of HA fragments. Small 
fragments that were initially restricted by the 3k membrane can move through the 10k 
membrane. This would also affect the mechanical stiffness of hydrogels formed in later steps, 
highlighting the influence of each synthesis and purification step. 
A significant advantage of HA microrods is that they are degradable by native 
physiological processes to accommodate new tissue growth46,47,104,105. While several studies have 
investigated the degradation behavior of covalently crosslinked HA hydrogels, it is necessary to 
characterize each new formulation since molecular weight, degree of methacrylation and weight 
percent can drastically affect degradation. In our study, we use lower molecular weight HA in 
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our synthesis to achieve high degrees of methacrylation (Figure 2.1B-C). Additionally, we can 
get higher concentrations of low molecular weight HA (LMWHA) compared to high molecular 
weight HA (HMWHA), allowing for fabrication of hydrogels in a greater range of stiffness 
(Figure 2.2). We used varying concentrations of hyaluronidase to understand the behavior of this 
degradation. For 100 mg/mL HA hydrogels, we observed an initial linear phase of degradation 
that was dependent on concentration of hyaluronidase (Figure 2.4C). This was followed by a 
second slow phase of degradation that was independent of hyaluronidase concentration. These 
data suggest that these HA hydrogels are first degraded through an enzyme mediated mechanism 
which break up the accessible HA chains on the surface of the hydrogels. When there is high 
crosslinking density, the enzyme will only degrade the exterior of the hydrogel, resulting in 
surface erosion. In contrast, looser hydrogel networks allow the enzyme to penetrate the interior 
and cause bulk degradation. This is also apparent by morphological analysis wherein lower 
weight percent HA hydrogels gradually lost mechanical integrity and eventually completely 
dissolved, while higher percent HA hydrogels became smaller over time, indicating surface 
degradation. 
We originally hypothesized that fibroblasts bind to HA microrods via CD44 receptors on 
the cell surface, activating a sequence of signaling cascades that induce phenotypic changes. 
Fibroblasts display a high content of CD44 receptor and conform well to the microrod 
topography, suggesting that fibroblasts are responsive to HA microrods in the local environment 
(Figure 2.8). However, both myocytes and fibroblasts exhibit focal adhesions to the HA 
microrod contour. The deposition of fibronectin to HA explains how cells are able to attach to 
HA, a material that is traditionally believed to be non-adhesive (Figure 2.9). This is consistent 
with previous reports that HA is nonadherent during the first few hours of culture, but becomes 
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adherent and amenable to cell attachment after several hours have passed120,121. One possibility is 
that CD44 facilitates fibroblast association with the HA microrods while fibronectin supports 
continuous attachment121,122. Additionally, it has been shown that modification of the HA 
backbone can reduce its affinity for CD44123. It is possible that our ~41% modification of the 
6C-OH is sufficiently high that it impairs the affinity of CD44 on the cell surface to the HA 
microrods. We therefore hypothesize that integrin binding is a key mechanism of interaction 
between fibroblasts and HA microrods, which may be amplified by other pathways involving 
HA and its receptors to cause phenotypic changes. Additional investigation is necessary to 
elucidate the precise interactions and mechanisms involved. 
 
2.5 Conclusion 
 In summary, we synthesized a UV-curable hyaluronic acid derivative that can be 
crosslinked into discrete microrods through photolithography. The stiffness and degradation 
kinetics of these microrods are easily tuned by varying HA concentration in the precursor 
solution. We further demonstrate that these microrods are highly interactive with cardiac 
fibroblasts and myocytes and capable of eliciting phenotypic changes through biophysical and 
biochemical pathways. The antifibrotic effects and therapeutic benefits of these microrods will 
be discussed in Chapter 3. 
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Figure 2.1. Synthesis and characterization of hyaluronic acid methacrylate. (A) Hyaluronic 
acid (100 kDa) was reacted with glycidyl methacrylate to add photosensitive pendant groups to 
the polymer backbone. (B) 1H-NMR was used to quantify the modification of HA (top) with 
methacrylate groups (red arrows). The product (bottom) had two methacrylate peaks at ~5.65 
ppm and ~6.1 ppm, which was compared to the acetamide peak (green arrows) at 1.85 ppm to 
calculate the degree of substitution. (C) A time course study was conducted on this reaction and 
showed that the reaction was complete after 24 hours with no increase in % methacrylation with 
increasing reaction time.  
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Figure 2.2. Stiffness characterization of hyaluronic acid hydrogels. A range of concentrations 
of HA methacrylate were used to fabricate HA hydrogels with elastic moduli between 1 kPa and 
160 kPa. The data are presented as mean ± SD (n = 3 per group).  
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Figure 2.3. Microrod fabrication and visualization. (A) HA microrods were fabricated by 
exposure of a thin film of HAMA to UV light through a photomask followed by development in 
water. (B) Brightfield images of uniformly produced HA microrods on a silicon wafer. (C)  
Fluorescent images of HA microrods labeled with fluorescein indicate expected dimensions on 
all axes. Scale bars = 100 µm. 
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Figure 2.4. Surface area and crosslinking density affect enzyme-mediated degradation of 
crosslinked HA. (A) HA hydrogels made from higher HAMA concentration have reduced rates 
of hyaluronidase-mediated degradation due to increased crosslinking density (n = 3 per group). 
(B) Images of HA hydrogels after 16 days of degradation in 100 U/mL hyaluronidase compared 
to 0 U/mL hyaluronidase. (C) 100 mg/mL HA hydrogels degraded in a range of hyaluronidase 
concentration suggest biphasic degradation patterns consisting of enzyme degradation on 
accessible fragments on the surface. Hydrolysis creates new accessible fragments which are 
degraded by enzyme in the second, slower phase of degradation (100 U/mL: n = 3, 10 U/mL: n = 
2, PBS: n = 3). (D) Images of 100 mg/mL HA hydrogels after 16 days of degradation in varying 
amounts of hyaluronidase.  
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Figure 2.5. Enzyme-mediated degradation of HA microrods occurs by surface erosion. (A) 
Crosslinking density has limited effect on HA microrod degradation due to high surface area to 
volume ratio (n = 3 per group). (B) Differential interference contrast (DIC) images of 100 
mg/mL HA microrods incubated in PBS (left) or 100 U/mL hyaluronidase (right) for 10 days 
demonstrates surface erosion of microrods. The data are presented as mean ± SD. Scale bars = 
100 µm. 
  
29 
 
 
Figure 2.6. Degradation of HA microrods in physiological concentrations of hyaluronidase. 
50 mg/mL HA microrods were degraded in 0.25 U/mL and 0 U/mL hyaluronidase to assess 
degradation in physiological concentrations of hyaluronidase. These microrods are expected to 
last over 2 weeks in the body. The data are presented as mean ± SD (n = 3 per group).  
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Figure 2.7. Cardiac fibroblasts interact with HA microrods in vitro. Fluorescent 
immunocytochemical staining show that neonatal rat ventricular fibroblasts are highly interactive 
with HA microrods. These interactions include wrapping around the microrods (A,B), spreading 
across the entire microrod surface (C), and forming focal adhesions to the edges of the microrod 
(D).  Actin (red), paxillin (green), nuclei (blue), microrod (cyan). Scale bars = 20 µm. 
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Figure 2.8. Interaction of HA microrods with primary neonatal ventricular myocytes and 
fibroblasts in co-culture. (A) Interaction of myocytes (green arrows) and fibroblasts (white 
arrows) with HA microrods via focal adhesions (paxillin). (B) CD44 receptor is more abundant 
in fibroblasts (white arrows) than in myocytes (green arrows). Staining of nucleus and HA 
microrods by DAPI (blue); F-actin by phalloidin (red); paxillin and CD44 with their respective 
antibodies (green). Scale bars = 20 µm. 
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Figure 2.9. Fibronectin binds to HA microrods. Merged fluorescence and phase contrast 
images for (A) microrods incubated with fibronectin and (B) microrods with PBS alone. Scale 
bars = 20 µm.    
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Chapter 3 – Assessment of HA Microrod Administration for the Treatment of Cardiac 
Fibrosis After MI 
 
3.1 Introduction 
Ischemic heart disease is the leading cause of death worldwide, accounting for nearly 10 
million deaths in 2016124. While advancements in preventive and acute treatment of myocardial 
infarctions (MI) have improved patient outcomes and reduced mortality rates, the resulting tissue 
damage initiates pathological repair mechanisms that culminate in the formation of non-
contractile scar tissue3,5,10–13. This progressive tissue stiffening results in additional stress on the 
heart and reduced cardiac output, which contributes to infarct expansion and left ventricular 
dilatation3,7,125. The lack of treatment for this maladaptive response leads to challenging chronic 
complications and eventual heart failure in a growing patient population. 
Within the past 5 years, there have been significant efforts towards developing 
intramyocardial hydrogel injections for cardiac tissue repair after MI42–45,126–128. These hydrogels 
act as bulking agents to thicken and mechanically stabilize the damaged myocardium, decreasing 
left ventricle (LV) wall stress and limiting LV expansion. Furthermore, these materials can be 
tailored for delivery of pharmacological agents, biologics, or stem cells to support tissue 
regeneration through several mechanisms. Among the multitude of materials that have been 
investigated, injectable hyaluronic acid (HA) hydrogels have gained increasing attention for 
cardiac tissue regeneration due to the implications of HA in wound healing52–55. 
 While these approaches have seen success in hindering the progression of heart failure, 
there lies significant potential in reprogramming native repair processes for healthy cardiac 
repair. In healthy tissue, cells intimately interact with the native extracellular matrix (ECM), 
which plays a critical role in regulating the organization, proliferation and differentiation of 
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progenitor and mature cell populations129–131. Upon injury, substantial cell death and 
upregulation of ECM degrading enzymes causes release of latent chemical factors as well as the 
loss of cell-cell and cell-ECM contacts. This dramatic loss of cellular tension and anchorage 
stimulates the remaining fibroblasts to undergo phenotypic changes that ultimately lead to 
excessive deposition of scar tissue7,11–14,132–134. We have previously demonstrated the use of 
polymeric microstructures to study how microscale topographical cues affect the fibrotic 
response91–93,114. These microstructures provided anchors for cardiac fibroblasts with anchors in a 
softer 3D environment and were able to reduce cell proliferation, myofibroblast differentiation 
and expression of collagens. Polyethylene glycol dimethacrylate (PEGDMA) microstructures 
were later used to attenuate cardiac fibrosis and reduce degeneration of cardiac function in a rat 
model of MI93. 
 In chapter 2, we demonstrated the development of hyaluronic acid-based microrods for 
interaction with cardiac fibroblasts and myocytes. In this work, we demonstrate the application 
of these HA microrods towards comprehensive cardiac tissue repair after MI. We were able to 
promote cell growth, attenuate myofibroblast transformation, and preserve myocardial structure 
and function after MI to a greater extent than previously reports utilizing this bioactive and 
biodegradable material. 
 
3.2 Materials and Methods 
3.2.1 Materials 
 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (HMPP) and 2-methylbutane 
were purchased from Sigma-Aldrich (St. Louis, MO). Sodium hyaluronate (100 kDa) was 
purchased from Lifecore Biomedical (Chaska, MN). Hyaluronic acid methacrylate was custom 
35 
 
synthesized per protocols described in chapter 2. Collagenase type-II was purchased from 
Worthington Biochemical (Lakewood, NJ). 
 
3.2.2 Fabrication of HA microrods 
A 0.5% w/v solution of HMPP was prepared and used to dissolve hyaluronic acid 
methacrylate at 75 mg/mL or 100 mg/mL. Once fully dissolved, the precursor solution was 
centrifuged at max speed for 10 minutes to remove impurities. A 15 µm thick layer of this 
solution was deposited onto a piranha cleaned silicon wafer and exposed through a photomask to 
a 365 nm UV light source using a Karl Suss Mask Aligner to crosslink the hyaluronic acid 
methacrylate in rod shapes (15 µm × 100 µm). The microrods were then gently scraped off the 
surface of the wafer using a cell scraper and collected into water, allowing uncrosslinked regions 
of hyaluronic acid methacrylate to fully dissolve. The microrods were passed through a 150 µm 
mesh filter to remove large particles and washed thoroughly by centrifugation. The microrods are 
sterilized with 70% ethanol and resuspended in saline or cell culture medium prior to use. 
 
3.2.3 Fibroblast and myocyte cell culture 
NIH 3T3 mouse fibroblasts (ATCC, Manassas, Virginia) were cultured in the complete 
medium consisting of Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Primary neonatal rat ventricular fibroblasts (NRVFs) and myocytes 
(NRVMs) were isolated from primary heart cultures obtained from neonatal rats according to 
Institutional and National Institutes of Health guidelines. Hearts were removed from 1- to 2-day-
old Sprague-Dawley rats and cells isolated using collagenase type II, per previously established 
protocol111. Fibroblasts, which had been separated from myocytes during isolation, were cultured 
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an additional 2 days before detaching cells with trypsin and seeding in new dishes for 
experiments. 
 
3.2.4 NIH 3T3 proliferation and gene expression 
NIH 3T3 mouse fibroblasts were harvested and cultured with HA microrods (100 
mg/mL) at a high ratio (1:5) or a low ratio (1:20) of microrods to cells. Cell proliferation was 
assessed at 24, 48 and 72 hours after initial seeding using a Cyquant assay (ThermoFisher 
Scientific, Waltham, MA). Experiments were done in triplicate. For gene expression studies, 
NIH 3T3 mouse fibroblasts were cultured with HA microrods for 48 hours. Genetic material was 
harvested and purified using the RNeasy Miniprep kit. RNA was converted into cDNA using the 
iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). A Viia7 qPCR machine (Life 
Technologies, Carlsbad, CA) was used to measure relative expression levels of gene targets as 
compared to a housekeeping gene. Expression levels of all genes were evaluated using SYBR 
Green Mastermix (Life Technologies, Grand Island, NY) and custom-made DNA primers 
(Integrated DNA Technologies, Coralville, IA) in triplicate for three biological replicates (Table 
3.1). 
 
3.2.5 Kymograph analysis of cardiomyocyte contractility  
Neonatal ventricular cardiomyocytes were plated on fibronectin-coated dishes (10 
μg/mL) or fibronectin-coated dishes with HA previously deposited (10,000 HA microrods/dish). 
A subset of dishes were chronically exposed to hyaluronic acid (0.042 mg) starting on the plating 
day. On the second day of incubation, kymographs derived from line scans with DIC 
illumination were used to derive cardiomyocyte contractile properties as described previously135. 
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For HA microrods, line scans were developed on myocytes with close proximity to the HA 
microrods. 
 
3.2.6 Infarct model and microrod injections 
The animal protocol for induction of MI was approved by the Committee for Animal 
Research of the University of California, San Francisco and was performed in accordance with 
the recommendations of the American Association for Accreditation of Laboratory Animal Care.  
The ischemia-reperfusion model used in this study has been extensively tested in our lab. 
All injections were performed successfully and there were no complications resulting from 
surgery or injection in any animal. Protocols were approved by the IACUC of UCSF. 
To produce the MI model, female Sprague-Dawley rats (180–220 g) underwent occlusion 
of the left anterior descending coronary artery for 30 minutes followed by reperfusion while 
under general anesthesia achieved by inhalation of 2% L/min isoflurane136. The chest was then 
closed and the animal was allowed to recover. The rats were randomized two days after MI to 
saline-injected, HA solution-injected, or microrod-injected treatment groups, and were given one 
intramuscular injection into the heart wall under blinded conditions via ultrasound guided 
transthoracic injection using a 29-gauge syringe136. Each injection consisted of 50 µL of sterile 
0.9% sodium chloride solution (n = 7), HA dissolved in sodium chloride solution at 4.2 mg/mL 
(n = 9), or 50,000 of microrods in sodium chloride solution (n = 7). Preliminary studies showed 
that 75 mg/mL HA microrods outperformed the 100 mg/mL microrods. 75 mg/mL HA 
microrods were used for all microrods injections presented in this study. Each injection was 
delivered to the center of the infarct region as visualized by hyperechoic signal on ultrasound. 
Successful injection was confirmed by a slight local increase in ultrasound signal in the vicinity 
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of the syringe, as well as a brief thickening of the LV wall. 
 
3.2.7 Echocardiography 
Transthoracic echocardiography was performed with a 15-MHz linear array transducer 
system (Sequoia c256, Acuson, Erlangen, Germany) on all animals under 2% L/min isoflurane. 
Echocardiography was done prior to injection on day two post-MI and six weeks post-injection 
using standard methods that have been performed reproducibly in our lab93,136. To determine left 
ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and 
ejection fraction (EF) at 48 hours and six weeks, the ventricular shadow was outlined in both 
systole and diastole and the single plane area length algorithmic method was applied. Two-
dimensional images were obtained in both parasternal long- and short-axis views at the papillary 
muscle level. Stroke volume (SV) was calculated by SV = LVEDV-LVESV, while change in EF 
was calculated by ΔEF = EF6 weeks-EF2 days. Transverse images were obtained at three levels: 
basal (at the tip of the mitral valve leaflets), middle (at the papillary muscle level), and apical 
(distal to papillary muscle but before the cap of the cavity). All image analyses were performed 
in a blinded fashion. In cases where the ventricular shadow was not clearly identifiable in the 48 
hour or six-week image, the heart in question was excluded from echocardiographic analyses. 
Cases where ejection fraction was above 50% at 48 hours were excluded because they indicated 
an insufficient infarct model. 
 
3.2.8 Histology 
Sacrifice was performed after six weeks by maintaining the animal at 5% L/min 
isoflurane for five minutes, followed by bilateral thoracotomy and injection of potassium 
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chloride into the right atrium to arrest the heart in diastole. The heart was then extracted and 
frozen in OCT (Sakura Finetech USA, Inc., Torrance, CA) on 2-methylbutane (Sigma Aldrich, 
St. Louis, MO) on dry ice and sectioned for histology and image analysis. Tissue blocks were 
cryo-sectioned at a thickness of 10 µm starting at the apex of the left ventricle and collecting 10 
serial sections every 350 µm until 100 sections were collected. Sections were stained with H&E 
stains, Masson’s Trichrome stain and Picrosirius red stains using standard protocols. For 
immunofluorescent stains, tissue sections were air dried and blocked with 10% serum, followed 
by incubation with primary and secondary antibodies using standard protocols. In brief, samples 
were incubated overnight with primary antibodies at 4 °C in a solution of 0.1% Triton X-100, 
0.05% Tween-20, 10% goat serum and 1% BSA in PBS (anti-vimentin, anti-CD68, anti-CD3, 
anti-paxillin; Abcam, Cambridge, United Kingdom). After rinsing, secondary antibody was 
added for 45 minutes at room temperature. DAPI and AlexaFluor 546 phalloidin were added as a 
counterstain (Thermofisher Scientific, Waltham, MA). 
 
3.2.9 Image analysis 
A Nikon confocal microscope was used for fluorescence imaging of fibroblast 
interactions with HA microrods in vitro. Single-plane and Z-stack images were obtained using a 
40x Nikon objective. Primary antibodies for paxillin [ab32084] and CD44 [ab157107] (Abcam, 
Cambridge, MA) were used at 1:250 and 1:1000 dilutions, respectively, incubated overnight, 
then counterstained with secondary antibody (A21207, Thermofisher Scientific, Waltham, MA), 
rhodamine phalloidin (R415, Thermofisher, Waltham, MA), and DAPI (H-1200, Vector 
Laboratories, Burlingame, CA).  
For whole heart histology, brightfield images were taken using a Nikon 6D optical 
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microscope (NIKON Instruments, Inc., Melville, NY) with 4–20x magnification (H&E, 
Masson’s Trichrome, Picrosirius Red). Fluorescent images were taken with a Nikon spinning 
disc confocal microscope at 40x magnification. All quantifications were performed using Nikon 
Elements. For wall thickness analysis, the minimum length across the infarct area was measured 
for each tissue section. The absolute minimum length across all available sections in a given 
heart sample was selected as the minimum wall thickness. 
For collagen analysis, five sections of each heart were selected from throughout the 
coronal plane of the infarct zone and stained with picrosirius red to assess the distribution and 
density of collagen in the injured hearts. These sections were imaged under brightfield as well as 
under polarized light to visualize the collagen fibers. Infarct area was quantified and normalized 
to total area of the left ventricular free wall. 
 
3.2.10 Statistical analysis 
All values for continuous variables are listed as the mean ± one standard deviation, unless 
otherwise indicated. In vitro and in vivo analysis was performed using a one-way analysis of 
variance (ANOVA), followed by multiple comparison by Holm-Sidak correction to identify 
differences between groups. 
 
3.3 Results 
3.3.1 Influence of hyaluronic acid microrods on fibroblasts and myocytes in vitro 
We grew NIH-3T3 fibroblasts with HA microrods to evaluate the effect of HA microrods 
on fibroblast behavior in vitro. Interestingly, interaction with HA microrods increased fibroblast 
proliferation when cultured over three days (Figure 3.1A). NIH-3T3 fibroblasts grown with HA 
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microrods in a 1:5 ratio of microrods:cells had increased proliferation rates compared to control 
cells grown on tissue culture plastic (p < 0.01). This contrasts with previous studies using 
PEGDMA microrods, which reduced fibroblast proliferation92. This can be attributed to HA 
having additional cell growth properties compared to PEG, which is considered relatively 
bioinert. Despite the increased proliferation of fibroblasts, gene expression studies showed a 
decrease in key fibrosis markers. In cells grown with HA microrods, there was a dose-dependent 
decrease in expression of collagen I (Col1A2) and alpha smooth muscle actin (αSMA), markers 
of a myofibroblast phenotype. (Figure 3.1B). In cells cultured in a 1:20 ratio of microrods:cells, 
Col1A2 expression was reduced to 0.31 ± 0.04 fold expression relative to cells grown without 
microrods (p < 0.001) while αSMA was reduced to 0.09 ± 0.02 fold expression (p < 0.001). This 
effect was more profound when the number of microrods was increased to 1 per 5 cells. 
Additionally, HA microrods significantly reduced TGFβ1 expression and Smad3 expression 
(Figure 3.1C, p < 0.05). These data suggest that the HA microrods act on the TGFβ-signaling 
pathway to reduce the myofibroblast phenotype. We further examined the effect of HA 
microrods on the expression of matrix metalloproteinases (MMPs), specifically MMP2 and 
MMP9. These MMPs are upregulated following myocardial infarction to facilitate the initial 
breakdown and remodeling of ECM. We found that MMP2 was significantly reduced in 
fibroblasts cultured with HA microrods compared to control cells (Figure 3.1D, p < 0.05), 
suggesting that HA microrods may attenuate aberrant ECM breakdown during the initial days 
after MI. 
The effect of HA microrods on cardiomyocyte function in vitro was also evaluated. 
Neonatal rat ventricular myocyte (NRVMs) were cultured in the presence of HA microrods or 
soluble HA for 48 hours and compared to control cells. Kymographs were derived from line 
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scans under DIC illumination to determine the beats per minute and time to peak tension (Figure 
3.2). No significance was found between groups, suggesting that neither HA microrods nor free 
HA interfere with the contractile properties of the NRVMs. Taken together, these results suggest 
that HA microrods show promise as a therapeutic strategy to promote regenerative processes in 
the infarcted myocardium while mitigating pathological scarring. 
 
3.3.2 Therapeutic effects of hyaluronic acid microrods in a rat model of MI 
An infarct was induced in rats by ischemia reperfusion to generate a cardiac fibrosis 
model. HA microrods, soluble HA or saline were delivered into the infarct zone by ultrasound-
guided, transthoracic injection. Total HA mass was kept equal for soluble HA and HA microrod 
injections to account for the material effect of HA.  
HA microrod treatment was shown to result in improved functional outputs (Figure 3.3, 
Figure 3.4). At six weeks, stroke volume was significantly greater in animals treated with HA 
microrods compared to animals treated with saline (Figure 3.3C, p < 0.01). Change in ejection 
fraction (EF) was determined by taking the difference in ejection fraction measured at 2 days 
(before injection) and 6 weeks (Figure 3.4). Rats treated with HA microrods have a positive 
improvement in ejection fraction (5.91% ± 3.67%) compared to HA solution controls (-0.36% ± 
4.20%, p < 0.05) and saline controls (-8.22% ± 7.28%, p < 0.001). Animals treated with soluble 
HA also exhibited significant improvements in ejection fraction compared to saline (p < 0.01), 
suggesting beneficial effects from the material alone. There was no significant difference in left 
ventricular end diastolic volume (LSEDV) and left ventricular end systolic volume (LVESV) 
(Figure 3.3A-B). 
Cryosections of heart tissue were stained with hematoxylin and eosin (H&E), Masson’s 
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trichrome and Picrosirius red to evaluate the effect of microrod injection on the progression of 
cardiac fibrosis, as compared to injections of soluble HA or saline (Figure 3.5). Wall thickness 
measurements were performed on sections throughout the heart where the left ventricle cavity 
was visible. The left ventricular wall of hearts treated with HA microrods had greater minimum 
wall thickness (1.22 ± 0.38 mm) compared to saline treated hearts (0.70 ± 0.24 mm), which 
exhibited significant wall thinning (Figure 3.6A, p < 0.05). Animals treated with HA solution 
had moderate wall thinning compared to saline treated and HA microrod treated hearts (1.03 ± 
0.21 mm). Heart sections were then stained with Masson’s trichrome and Picrosirius red to 
quantify the size and collagen content of the infarcts. A comparison of rats treated with HA 
microrods or soluble HA to those treated with saline showed moderate, although not significant, 
reduction in collagen deposition in the free wall of the left ventricle (Figure 3.6B, p = 0.1). 
Examining the HA microrod injection area, we noted that the collagen deposited around 
the microrods was much less dense and not visible under polarized light, suggesting a local 
decrease in collagen deposition and maturation (Figure 3.7B,D). This contrasts with areas distant 
from the injection site where more dense collagen fibrils are present (Figure 3.7C,E). 
Immunofluorescence staining with markers of vimentin for fibroblasts and CD68 for 
macrophages indicated that both CD68-positive macrophages and vimentin-positive, CD68-
negative fibroblasts were present at the injection site (Figure 3.8A). Additionally, we found that 
fibroblasts surrounding the HA microrods had more rounded nuclei compared to those found 
away from the injection site, which were spindle shaped and characteristic of activated 
myofibroblasts (Figure 3.8B). Immunofluorescent staining of actin and paxillin also showed that 
cells within the injection site interacted with the HA microrods and formed focal adhesions along 
the edges of the microrods (Figure 3.9). It is likely that this interaction locally reduces fibroblast 
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activation in vivo as was seen in vitro. 
 
3.4 Discussion 
In this work, we investigated the use of HA microrods to attenuate the fibrotic phenotype 
associated with pathological LV remodeling and encourage the repair of damaged cardiac tissue 
after MI. Our results indicate that HA microrods increase fibroblast proliferation while also 
reducing expression of fibrotic genes such as collagen I and alpha smooth muscle actin. 
Additionally, these microrods can be injected into the infarcted myocardium to deliver 
biophysical and biochemical cues to preserve myocardial wall structure and function. 
Previous studies have utilized bulk HA injections to mechanically support the damaged 
myocardium and preserve cardiac function after MI51–54. These strategies typically use 
biocompatible crosslinking chemistries to form the HA hydrogel in situ. While this allows for 
noninvasive catheter-based delivery, the gelation kinetics of HA in these cases can present 
significant challenges. Rapid gelation can lead to clogging of the catheter during the multiple 
injections required for treatment, while slow gelation results in diffusion of the hydrogel material 
into the tissue, leading to compromised hydrogel structure and mechanical properties44,137. 
Utilizing a rigorous interdisciplinary approach, we developed HA microrods to overcome these 
limitations. These discrete microstructures were fully crosslinked and characterized before 
injection and can be delivered to the myocardial wall by catheter injection without risk of 
clogging. Additionally, the ability to crosslink prior to injection gives tighter control over cell 
shaped morphology and hydrogel stiffness in the physiologic range, which are both crucial 
properties for mechanotransduction94–96.  
Within the past several decades, mechanical signaling has gained appreciation as a 
powerful mechanism for controlling cell behavior94–100. This includes mechanical stiffness, shear 
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forces and topography. In contrast to bulk polymer injections that reduce wall stress by providing 
mechanical support and preventing LV dilation, discrete HA microrods provide local 
micromechanical and biochemical signals to reprogram the cells of the myocardium. We have 
used both polypropylene microfibers and polyethylene glycol (PEG) microstructures to supply 
external mechanical cues and reduce myofibroblast differentiation91–93. HA microrods were 
shown to attenuate the fibrotic response to a greater degree than previously developed materials, 
likely due to the added biochemical effects of HA (Figure 3.1). Chopra et al reported the role of 
HA receptor binding in integrin mediated mechanotransduction121,122. Mesenchymal stem cells 
and fibroblasts were able to anchor to soft HA hydrogels containing fibronectin and observed 
increased rates of proliferation compared to soft polyacrylamide gels with fibronectin. Our cell 
proliferation data are consistent with these results, suggesting that the pro-proliferative effects of 
HA are preserved. Additionally, expression of key myofibroblast markers, αSMA and collagen 
1, were reduced in NIH-3T3 fibroblasts to a greater extent compared to our studies with PEG 
microrods, an inert microtopographic cue92. 
The results of our in vivo experiments support these observations as well. The 
introduction of HA microrods 2 days after the initial infarct provides anchors for fibroblasts, 
macrophages and other cell types. Cells found at the injection site interacted with the microrods 
through focal adhesions, likely due to the increased stiffness relative to surrounding tissue 
(Figure 3.9). We propose that this stiffness differential leads to attenuation of the myofibroblast 
phenotype, manifesting in decreased deposition of collagen, reduced wall thinning and improved 
cardiac output. Similar to our in vitro results, HA microrods improved LV ejection fraction 
(5.91% ± 3.67%) to a greater degree as compared to previous studies using PEG microrods (-
2.59% ± 8.11%)93. At 6 weeks, cardiac function of HA microrod treated hearts surpassed 
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baseline, post-infarct function, highlighting the potential of this technology to promote 
endogenous repair mechanisms not previously seen in materials-based approaches. We 
investigated whether this was due solely to the biological effect of HA by injecting a solution of 
HA into the heart wall after MI. The concentrations used were not high enough to generate a stiff 
gel, yet there were also improvements on cardiac function (Figure 3.3, Figure 3.4). This is likely 
due to the wound healing properties of HA, which may contribute to the results seen in studies 
involving bulk HA injections50,106,138.  
The goal of this study was to fabricate bioresorbable microstructures capable of 
delivering biophysical and biochemical cues and evaluate their potential for treating the 
progression of cardiac fibrosis post-MI to improve functional outcomes. These HA microrods act 
through mechanotransduction pathways to reduce fibrosis and maintain the structural integrity of 
the myocardium. Additionally, crosslinked HA can be compared to high molecular weight HA, 
which has anti-inflammatory effects that can limit pathological ECM remodeling during the 
initial days after an infarct46,104,106,107. Throughout degradation, these HA microrods are expected 
to release HA oligosaccharides that have been demonstrated to promote wound healing46,49,106,139. 
While it is difficult to investigate and tune the temporal interplay of mechanotransduction 
pathways and biochemical HA signaling pathways, our findings demonstrate that these two 
modes of action have significant implications for cardiac regeneration. By probing these 
individual pathways and responses, we will be able to optimize this novel microstructure-based 
technology to initially reduce the aberrant fibrotic response with micromechanical cues and later 
stimulate vascularization and other endogenous repair mechanisms for comprehensive 
myocardial repair. 
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3.5 Conclusion 
Our acellular microrod approach is unique and provides biodegradable and bioactive 
micromechanical signals to directly limit fibrosis and favorably influence the microenvironment 
to attenuate myocardial wall thinning and improve LV function.  Introduction of these microrods 
to the injured heart provided anchors to surrounding cells during initial inflammatory processes 
when the ECM is being degraded. This micromechanical interaction attenuated the fibrotic 
phenotype and improved morphological and functional outcomes in a rat ischemia-reperfusion 
model of MI. In the future, this innovative strategy can be co-implemented with pharmacologic 
and cell-based therapies to further advance our limited clinical capabilities in treating the chronic 
complications of MI.  
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Target Gene Forward Primer (5’->3’) Reverse Primer (5’->3’) 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Rpl19 CATTTTGCCCGACGAAAGGG GATCTGCTGACGGGAGTTGG 
αSMA GCTGCTCCAGCTATGTGTGA CCATTCCAACCATTACTCCCTGA  
Col1α2 AAGGGTGCTACTGGACTCCC  TTGTTACCGGATTCTCCTTTGG  
MMP2 CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC 
MMP9 GGACCCGAAGCGGACATTG CGTCGTCGAAATGGGCATCT 
TGFβ1 GGACTCTCCACCTGCAAGAC CTGGCGAGCCTTAGTTTGGA 
TβRII ACGTTCCCAAGTCGGATGTG TGTCGCAAGTGGACAGTCTC 
Smad3 AAGGCGACACATTGGGAGAG GGGCAGCAAATTCCTGGTTG 
 
Table 3.1. Primer pairs for qPCR. GAPDH, glyceraldehyde 3-phosphatedehydrogenase; 
rPL19, ribosomal protein L19, αSMA, alpha smooth muscle actin; Col1α2, collagen type I, 
MMP2, matrix metalloproteinase-2; MMP9, matrix metalloproteinase-9; TGFB1, transforming 
growth factor beta-1; TBRII, TGFB receptor type II; Smad3, SMAD family member 3.  
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Figure 3.1. HA microrods modulate the phenotype of fibroblasts in vitro. (A) NIH-3T3 
fibroblasts cultured with HA microrods have increased proliferation compared to control cells (n 
= 3 per group). (B) NIH-3T3 fibroblasts exhibit dose-dependent reduction in Col1A2 and αSMA 
expression when cultured with HA microrods for 48 hours (n = 3 per group). (C) HA microrods 
reduce TGFβ1 and Smad3 expression in NIH-3T3 fibroblasts when cultured at a density of 1 rod 
per 5 cells. (D) MMP2 expression is reduced in NIH-3T3 fibroblasts cultured with HA microrods 
at a density of 1 rod per 5 cells. The data are presented as the mean ± SD. *p < 0.05, **p < 0.01, 
***p < 0.001. 
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Figure 3.2. HA microrods or soluble HA do not interfere with neonatal ventricular 
cardiomyocyte contractility. Myocytes were plated on glass-bottom dishes (control), in the 
presence of HA microrods, or chronically incubated with 0.042 mg of HA per dish (HA). 
Kymographs reveal no significant difference in (A) beats per minute, or (B) time to peak tension 
relative to control measurements (mean ± SD; n = 15, 15, and 14 for control, HA microrods, and 
HA, respectively). The data are presented as the mean ± SD. 
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Figure 3.3. HA microrods improve functional outcomes after MI. Echocardiography was 
used to measure the (A) end systolic volume and (B) end diastolic volume immediately prior to 
injection (2 days after MI), as well as 6 weeks after injection in rats treated with saline (n = 6), 
soluble HA (n = 9) and HA microrods (n = 7). (C) Stroke volume and (D) ejection fraction were 
quantified per animal. Animals treated with HA microrods had significantly increased stroke 
volume and ejection fraction compared to saline controls. The data are presented as the mean ± 
SD. **p < 0.01. 
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Figure 3.4. Ejection fraction is significantly improved in rats treated with soluble HA and 
HA microrods. Echocardiography was used to compare the ejection fraction (EF) 2 days after 
MI (immediately prior to injection) and 6 weeks after injection in rats treated with saline (n = 6), 
soluble HA (n = 9) and HA microrods (n = 7). Rats treated with HA microrods have significantly 
higher change in EF over rats treated with saline or HA solution. The data are presented as the 
mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3.5. Histological assessment of HA microrod and soluble HA treatment after MI. 
Cardiac tissue sections were stained with H&E, Masson’s Trichrome and Picrosirius red to 
visualize cell infiltration, vascularization and scar tissue formation. Scale bars = 2 mm.  
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Figure 3.6. HA microrods attenuate left ventricular remodeling after MI. (A) Left 
ventricular wall thinning was significantly reduced in hearts treated with HA microrods (n = 6) 
compared to saline injection (n = 7). Hearts treated with HA solution had moderate but not 
significant wall thinning (n = 8). (B) Tissue sections were stained with picrosirius red stain and 
visualized under polarized light. Fibrosis area in the free left ventricular wall was measured and 
normalized to total area. While not significant (p = 0.1), fibrosis appears to be moderately 
reduced after injection of soluble HA and HA microrods. The data are presented as the mean ± 
SD. 
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Figure 3.7. HA microrods interact with fibroblasts in vivo and locally reduce collagen 
deposition. (A) A representative Picrosirius red stained section of a HA treated heart. The dotted 
shape indicates the injection site. Collagen around the injection site (B,D) was sparse compared 
to far away from the injection site (C,E). The collagen near the microrods (white arrows) is loose 
and does not appear under polarized light, while the collagen away from the injection site 
matures into dense bundles. Scale bars = 2 mm (A) and 200 µm (B-E). 
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Figure 3.8. Characterization of cell type and morphology in the injection and infarct sites. 
(A) Confocal images of cells stained for vimentin, CD68 and nuclei show that both macrophages 
(CD68 positive, red arrow) and fibroblasts (vimentin positive, CD68 negative, white arrow) are 
present around the microrods. These cells appear to adopt a more rounded phenotype. (B) 
Fibroblasts (white arrows) located in the infarct scar and far from the microrods adopt a more 
stretched out morphology, characteristic of an activated phenotype.  Scale bars = 20 µm. 
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Figure 3.9. Fibroblasts locally interact with HA microrods in vivo through focal adhesions. 
Confocal images of microrods show that cells interact closely with HA microrods in vivo. Cells 
formed distinct focal adhesions (white arrow) formed along the edges of the microrods. Tissues 
were stained for nuclei (blue), actin (red) and paxillin (green). Scale bars = 10 µm. 
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Chapter 4 – Novel Functionalization of Polymeric Microrods for Drug Delivery and Tissue 
Engineering Applications 
 
4.1 Introduction 
As described in the previous chapters, microtopography is very powerful for tissue 
engineering applications. While impactful through a biophysical mechanism alone, one notable 
benefit of using polymeric microstructures is that they can be modified with a variety of 
chemistries to impart additional functionalities for drug delivery or tissue engineering 
applications. In this chapter, we present a collection of studies that illustrate the boundless 
potential of polymeric microstructures as both research and therapeutic materials. 
 
4.2 Materials and Methods 
4.2.1 Materials 
 Poly(ethylene glycol) dimethacrylate (PEGDMA, Mn = 750), N-vinylpyrrolidone (NVP), 
2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (HMPP), l-alanine, 2-aminoethyle 
methacrylate (AEMA), Tween 20, iron(II) chloride tetrahydrate, iron(III) chloride hexahyrate, 
ammonium hydroxide, tetraethyl orthosilicate (TEOS), and (3-mercaptopropyl)trimethoxysilane 
(MPTMS) were purchased from Sigma Aldrich (St. Louis, MO). Fluorescein-NHS, N′-
ethylcarbodiimide hydrochloride (EDC), and N-hydroxysulfosuccinimide (NHSS) were 
purchased from Thermo-Fisher Scientific (Waltham, MA). DNA-NHS was custom synthesized 
by the Gartner Lab at the University of California, San Francisco. Hyaluronic acid (HA) 
methacrylate was synthesized in our lab as described in chapter 2.  HepIII 
(GEFYFDLRLKGDKY) and HepIII-FITC were custom synthesized by GenScript (Piscataway, 
NJ).  NVP-AEW541 was purchased from ApexBio (Houston, TX). 
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4.2.2 Preparation of alanine-loaded PEGDMA microrods 
Precursor solutions consisting of PEGDMA (80%, 50% or 20% v/v), alanine (15 mM, 
150 mM, 600 mM respectively) and 10% NVP containing 100 mg/mL HMPP were prepared in 
phosphate buffered saline (PBS). The solutions were then vortexed to ensure thorough mixing of 
reagents. 
Microrods were fabricated by standard photolithographic techniques92,93. Briefly, the 
precursor solution was spun to a 15 µm thick layer onto a piranha-solution-cleaned silicon wafer 
(Addison Engineering, San Jose, CA) and exposed through a photomask to a 365 nm UV light 
source using a Karl Suss MJB3 mask aligner (Suss Microtec, Garching, Germany) to crosslink 
the desired regions in the shape of microrods (100 µm × 15 µm). The microrods were briefly 
developed in deionized water, rinsed in isopropanol, and dried with nitrogen gas. Immediately 
prior to experiments, microrods were removed from the silicon wafer by rinsing the wafer with 
70% ethanol and gently scraping off the microrods with a cell scraper. The collected microrods 
were exchanged into PBS and immediately used. 
 Alanine-loaded microrods were incubated in 1 mL of PBS at 37 °C. At various time 
points, the microrods were pelleted by centrifugation and the supernatant was collected and 
replaced with fresh buffer solution. Alanine concentration was determined using a coupled 
enzyme reaction kit (Sigma-Aldrich). 
 
4.2.3 Cell viability experiments 
 20% PEGDMA microrods loaded with alanine were selected for cell culture experiments. 
Primary mouse islets were obtained and cultured at low density (20 islets/mL) or high density 
(1000 islets/mL) with and without alanine supplement in the form of free alanine or alanine 
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loaded microrods (104 and 2×104 microrods). After 5 hours, cell viability was quantified by 
propidium iodide staining and flow cytometry. 
 
4.2.4 Functionalization of PEGDMA microrods with surface molecules 
PEGDMA microrods were prepared as above with slight modifications to incorporate 
primary amine groups on the surface. Briefly, AEMA was dissolved in 50% dimethyl sulfoxide 
(DMSO) in water at 0, 10, 50, 100 and 500 mM concentrations. Additionally, a solution of 
HMPP photo-initiator was prepared in NVP at 100 mg/mL. A precursor solution was prepared 
by combining PEGDMA, AEMA solution, photo-initiator solution and water in a 70:10:10:10 
ratio. Microrods were fabricated by photolithography as described above. 
 Fluorescein-NHS was attached to the microrods in order to determine the conjugation 
capacity of the microrods. Aliquots of each microrod formulation were washed into 100 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 8.3) by centrifugation. To 
450 µL of microrods, 50 µL of 10 mM fluorescein-NHS in DMSO was added and reacted 
overnight. The microrods were then washed 3x by centrifugation prior to imaging and 
quantification. DNA-NHS was conjugated to the microrods through similar methods. 
 
4.2.5 Fabrication and loading of PEGDMA microrods with IGF-1R inhibitor 
A precursor solution containing 50% PEGDMA in PBS was mixed in a 10:1 ratio with 
NVP containing 100 mg/mL of the photo-initiator, HMPP. The solution was spun to a 15 µm 
thick layer on a piranha-solution-cleaned silicon wafer and exposed through a photomask to a 
365 nm UV light source using a Karl Suss MJB3 mask aligner to crosslink the desired regions in 
the shape of microrods (100 µm × 15 µm). The microrods were rinsed, scraped from the surface 
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gently using a cell scraper, and washed in PBS over 3 days to remove excess initiator. PEGDMA 
microrods were lyophilized in 1% Tween 20 and rehydrated in 2 mM (0.88 mg/mL) of NVP-
AEW541 over 3 days. 
 
4.2.6 Release kinetics of NVP-AEW541 
PEGDMA microrods loaded with NVP-AEW541 were washed 3x in 0.1% Tween 20 in 
PBS and reduced to a final volume of 150 µL. Over 9 days, samples were taken and the release 
buffer was replenished. Concentration of NVP-AEW541 in each sample was determined by 
absorbance at 285 nm, as well as by high performance liquid chromatography. Each replicate 
contained 8 × 105 microrods. 
 
4.2.7 Gene expression analysis of ATDC5 cells with NVP-AEW541 loaded microrods 
 Chondrogenic ATDC5 cells were cultured in complete medium consisting of 1:1 DMEM 
(2 mM L-glutamine, 4.5 g/L glucose) and Ham F12 supplemented with 5% fetal bovine serum 
(FBS), 1 U/mL penicillin/streptomycin, 0.25 ng/ml fungizone, insulin-transferrin-selenium (ITS, 
contains 1000 mg/L human recombinant insulin, 550 mg/L human recombinant transferrin and 
0.67 mg/L selenious acid). Secondary medium consisting of primary medium supplemented with 
0.05 mg/mL ascorbic acid and 10 mM B-glycerophosphate was used for experiments. Cells were 
plated in a 24-well plate and grown until confluent. Cells were serum starved for 8 hours prior to 
experiments and then treated with IGF-1 (100 ng/mL) along with free IGF-1R inhibitor, IGF-IR 
inhibitor loaded microrods (4x103, 8x103, 12x103) or blank microrods (4x103, 8x103, 12x103) for 
24 hours. The cells were then lysed to collect genetic material for qPCR analysis. 
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4.2.8 Animal model for post traumatic osteoarthritis 
A post-traumatic osteoarthritis model was obtained by placing the right lower leg of a 12-
week-old C57BL6 mouse between the upper and lower loading cups of a Bose computer 
controlled electromagnetic load actuator and load cell. A single bout of tibial compression 
overload (TCO) at 14 N is then applied. The resistance to the load is actively monitored until 
ACL ruptures has been confirmed by the changes in resistance. Following ACL rupture, mice 
were injected with 50 µL of IGF-1R inhibitor-loaded microrods (105 microrods/mL) or saline 
under 3% isoflurane. The mice were sacrificed after 3 weeks and tissue sections were obtained 
for histological analysis. 
 
4.2.9 Fabrication and surface functionalization of HA microrods 
HMPP was dissolved in water at a 0.5% w/v concentration. The resulting solution was 
used to dissolve hyaluronic acid methacrylate at 100 mg/mL. Once fully dissolved, the solution 
was centrifuged at max speed for 5 minutes to remove impurities. A 15 µm thick layer of this 
solution was deposited onto a piranha cleaned silicon wafer and exposed through a photomask to 
a 365 nm UV light source using a Karl Suss Mask Aligner to crosslink the HA methacrylate in 
rod shapes (15 µm × 100 µm). The microrods were then gently scraped off the surface of the 
wafer using a cell scraper and collected into water, where uncrosslinked regions of HA 
methacrylate would fully dissolve. The microrods were passed through a 150 µm mesh filter to 
remove large particles and washed thoroughly by centrifugation. The microrods are sterilized 
with 70% ethanol and washed with sterile water. 
 HepIII and HepIII-FITC were conjugated to HA microrods by EDC/NHS coupling. 
Briefly, HA microrods were first washed into 50 mM 2-(N-morpholino)ethanesulfonic acid 
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(MES) buffer (pH 5.5) by centrifugation. To these microrods, EDC and NHSS were added to a 
final concentration of 1 mM and 2 mM, respectively, and allowed to react for 30 minutes. A 
stock of HepIII was prepared (2 mg/mL) in water and diluted to 0.5 mg/mL with 100 mM 
HEPES buffer (pH 8.0). This was added to the activated microrods in equal volume and allowed 
to react overnight. The reaction was purified by centrifugation and washing in water. 
 
4.2.10 Synthesis of magnetic nanoparticles with a silica-thiol coating 
Superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized through 
coprecipitation of iron chloride salts under inert atmosphere. Briefly, 0.46 grams of iron(II) 
chloride tetrahydrate and 1.18 grams of iron(III) chloride hexahydrate were dissolved in 20 mL 
of deoxygenated water in a 100 mL round bottom flask. The solution was degassed further by 
nitrogen stream for 10 minutes and brought to 80 °C. 2.5 mL of 37% ammonium hydroxide was 
added under vigorous stirring, resulting in formation of a black precipitate of iron oxide. After an 
additional 30 minutes of stirring, a neodymium rare earth magnet was used to separate the 
nanoparticles from the supernatant. The nanoparticles were washed three times with deionized 
water and stored until further use. 
SPIONs were coated with a silica-thiol shell by a modified Stober method140. 100 mg of 
SPIONs were diluted in 50 mL of water. Separately, 1 mL of ethanol was combined with 1.78 
mL of TEOS and 1 mL of 2.4 mM hydrochloric acid and heated to 80 °C while stirring. The 
solution was cooled to room temperature and 0.59 mL of MPTMS was added and stirred for 20 
minutes. The silane solution was added dropwise to the SPION solution under stirring over the 
course of 2 hours. Particles were separated by neodymium magnet and sequentially washed twice 
with water, twice with ethanol and twice with acetone before storage in neutral pH water. 
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4.2.11 Fabrication of PEGDMA micromagnets 
Microrods were fabricated photolithographically as previously described92,93,141. To 
prepare the precursor solution, 1 mL of silica-thiol coated SPIONs in water were added to 9 mL 
of PEGDMA. Separately, 100 mg of HMPP was dissolved in 1 mL of NVP and added to the 
PEGDMA-SPION solution. A 15 µm thick layer of this solution was deposited onto a piranha-
cleaned silicon wafer and exposed to 365 nm UV light through a chrome mask to crosslink the 
solution into rod shapes (15 µm x 100 µm). The microrods were developed in water for 3 
minutes until the uncrosslinked hydrogel was dissolved. The wafer was then gently sprayed with 
isopropanol and dried with nitrogen gas. The microrods were collected of the wafer by soaking 
in ethanol followed by gentle scraping with a cell scraper. The crude solution was passed through 
a 150 µm mesh filter to remove large impurities. Magnetic microrods (micromagnets) were then 
concentrated using a neodymium magnet, resuspended in 70% ethanol and stored until further 
use.  
 
4.2.12 Culture of neonatal rat ventricular myocytes with magnetic microrods 
Ventricular cardiomyocytes (CMs) were isolated from 1-2 day old Sprague-Dawley rats 
as previously described142. CMs were seeded in the center portion of glass bottom dishes at a 
density of approximately 62,000 cells/cm2 in previously described plating media143. The 
micromagnets were washed three times and resuspended in plating media prior to use. After 24 
hours, dishes were washed with PBS to remove unattached cells, and 104 micromagnet were 
added to the entirety of the dish in plating media. CMs were cultured an additional 24-36 hours 
before beginning assays. 
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4.2.13 Contractility measurements after application of load to cardiomyocytes 
A ring-shaped neodymium magnet with axial magnetism was placed above the culture 
dish to attract a micromagnet that is well-adhered to a CM and able to apply a transverse load. 
The magnet used in experiments had a 14.3 kg pull force, 3.81 cm diameter, 1.905 cm inner 
diameter, and 0.635 cm thickness (#RX8C4, KandJ Magnetics). 
Line scan assays on spontaneously contracting CMs were carried out as previously 
described135. To provide clear markings for line scans, a line was chosen within the bounds of the 
cell along the direction of movement upon contraction. Line scan measurements were taken 
before and immediately after addition of a ring-shaped, axially-magnetized neodymium magnet 
on top of the dish designed to pull up on SPION microrods. 
Displacement was measured on the kymographs as the distance between the resting and 
fully contracted positions. The spontaneous beat frequency was counted over a period of 30 
seconds. The velocity of shortening of the contraction was determined by the amplitude (µm) for 
the linear portion of the rising phase divided by the time. The velocity of relaxation was similarly 
determined for the falling phase. 
 
4.2.14 Statistical analysis 
 All values for continuous variables are listed as the mean ± one standard deviation unless 
otherwise indicated. Student’s t-tests were performed to identify statistical differences between 
two groups. For experiments with three or more groups, one-way analysis of variance (ANOVA) 
was conducted, followed by Holm-Sidak correction for multiple comparisons to identify 
differences between groups. 
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4.3 Results 
4.3.1 Alanine-loaded PEGDMA microrods for nutrient delivery 
 PEGDMA microrods were successfully fabricated in a range of polymer concentration 
without affecting reproducibility or microrod dimensions (Figure 4.1A). At lower concentrations 
of PEGDMA, the microrods were less rigid and often appeared to be arched. This is due to a 
reduced number of crosslinks that could be formed between the polymer chains, which resulted 
in a looser polymer network. The mesh size of the hydrogel also increases, allowing for more 
rapid diffusion of alanine in and out of the microrods. 20% microrods had the highest amounts of 
alanine released after 4 days while 80% microrods had the lowest amount eluted (Figure 4.1B). 
This difference is partially a result of higher loading of alanine into the 20% PEGDMA 
microrods, as alanine is more soluble in precursor solutions containing less PEGDMA. 20% 
PEGDMA microrods contained 600 mM alanine, while 50% and 80% PEGDMA microrods 
were loaded with 150 mM and 15 mM alanine, respectively. Since our goal is to deliver as much 
alanine to pancreatic islets as possible, we proceeded with 20% PEGDMA microrods for cell 
viability experiments (Figure 4.1C). 
Islets were cultured at low density (20 islets/mL) and high density (1000 islet/mL) with 
and without alanine supplementation. Free alanine was previously shown to rescue the viability 
of nutrient-deprived primary islets in vitro144. Compared to low density islets, which exhibited 
80% viability, high density islets had 65% viability (Figure 4.1D). Consistent with previous 
reports, addition of 10 mM alanine restored the viability of HD islets. When cultured with 
alanine-loaded microrods, there was a dose dependent increase in cell viability. Interestingly, this 
effect was much greater than the addition of free alanine at 10 mM concentration despite the 
microrods being predicted to elute significantly less alanine. One possibility is that the islets are 
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grown in great proximity to the microrods such that local concentrations of alanine are much 
higher. This suggests that co-delivery of drug-loaded microrods with islets may improve the 
success of cell replacement therapies by providing the transplanted cells with the required 
nutrients to survive the first few days before they are able to integrate with the host vasculature. 
In sum, our results illustrate the tunability and therapeutic potential of microrods for drug 
delivery and tissue engineering applications.  
 
4.3.2 Surface functionalization of PEGDMA microrods 
 PEGDMA microrods were doped with AEMA to introduce primary amines to the 
hydrogel matrix. This provides a functional handle that can be used to attach carboxylic acid-
containing compounds to the microrods via carbodiimide coupling (Figure 4.2A). We 
demonstrate that increasing amounts of AEMA linearly increases the amount of fluorescein-NHS 
that can be attached to the microrod surface (Figure 4.2B-C). DNA molecules can also be 
attached to the microrod surface, which can later coordinate with small molecules, nanoparticles 
or cells that present the complementary strand of DNA (Figure 4.3A). Despite improved 
conjugation at higher concentrations of AEMA, there is also more nonspecific adsorption of 
DNA oligos to blank microrods, likely due to charge interactions between primary amines and 
the DNA molecules (Figure 4.3B). This can also affect microrod-cell adhesions, suggesting that 
presentation of DNA may not be necessary to promote this interaction. 
 
4.3.3 Treatment of post-traumatic osteoarthritis by IGF-1R inhibitor loaded PEGDMA 
microrods 
 PEGDMA microrods were also used as drug delivery devices for the treatment of post-
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traumatic osteoarthritis. NVP-AEW541, a small molecule IGF-1R inhibitor, was incorporated 
into the 50% PEGDMA microrods by diffusion. The drug-loaded microrods were washed into 
PBS and samples were collected for over 1 week to assess release kinetics (Figure 4.4). There 
was initial burst release during the first day, followed by a linear phase between 2 and 10 days. 
When added to ATDC5 cells treated with IGF-1, there was reduced expression of MMP9 and 
MMP13 compared to cells without microrods (Figure 4.5). A mouse model of PTOA was 
generated via a single bout of tibial compression overload to create an ACL rupture (ACLR) 
(Figure 4.6A). After 24 hours, saline or NVP-AEW541 loaded microrods were injected into the 
injured knee. µCT indicated that ACLR decreased bone volume/total volume (BV/TV) in the 
subchondral bone, while microrod treatment prevented bone loss (Figure 4.6B). Similarly, 
microrod treatment blunted the increase in trabecular spacing caused by ACLR (Figure 4.6C). 
Immunohistochemistry (IHC) of tissues isolated 2 weeks after injection indicated that microrods 
remained in the knee capsule (Figure 4.7). ACLR induced phosphorylation of Erk in the vehicle 
treated knees, but the effect was blocked in the inhibitor treated knees, verifying inhibition of 
IGF-1 signaling (Figure 4.8A-C). Safranin O/fast green staining revealed erosion of the articular 
cartilage and formation of osteophytes in the ACLR knees treated with vehicle, but these effects 
were not observed in the control knees or injured knees treated with microrods (Figure 4.8D-F). 
Additionally, ACLR increased the number of proliferating cell nuclear antigen (PCNA) positive 
articular chondrocytes (Figure 4.8G-I) and MMP-13 production (Figure 4.8J-L) in the vehicle-
treated injured knee, but these effects were blunted in the IGF-1R inhibitor-treated injured knee. 
VEGF production was also increased by ACLR, resulting in vessel formation within articular 
cartilage (as indicated by CD31) in the vehicle-treated injured knee, but these effects were 
blocked in the IGF-1R inhibitor-treated injured knee (Figure 4.9) 
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4.3.4 Surface modification of HA microrods with proangiogenic peptides 
 Surface functionalization of PEGDMA microrods was previous described in this chapter 
through incorporation of monomers containing primary amines. In contrast, HA microrods 
readily contain free carboxylic acid pendant groups which can be attached to primary amines via 
carbodiimide chemistry. We utilized EDC/NHS coupling to attach an amine-modified 
fluorescein, as well as a FITC-conjugated peptide, to HA microrods with minimal nonspecific 
adsorption (Figure 4.10). The peptide used, HepIII, is a fragment of collagen IV that has 
previously been demonstrated to promote neovascularization in a rat model of MI136,145,146. We 
grew human umbilical vein endothelial cells (HUVECs) with saline, bare HA microrods and 
HepIII functionalized microrods and quantified differences in proliferation rate. HA microrods, 
which were demonstrated in chapter 3 to increase fibroblast proliferation, had no effect on 
HUVEC proliferation (Figure 4.11). HUVECs cultured with HepIII modified microrods 
increased proliferation rate of HUVECs compared to control and bare HA microrods. This 
suggests that HepIII functionalized microrods may be able to promote tube formation in vitro 
and neovascularization in vivo while simultaneously reducing myofibroblast transformation. 
Animal experiments are currently underway to compare the effect of HepIII-functionalized HA 
microrods with bare HA microrods in a rat model of MI. 
 
4.3.5 Ferromagnetic microrods enable remote force manipulation of cardiomyocytes 
 Previously, PEGDMA microrods containing ferromagnetic particles were fabricated for 
applications in 3D imaging141. We reconfigured these microdevices for manipulation of cardiac 
muscle cells in culture in order to study contractile function in a live cell modality. Magnetic 
nanoparticles were synthesized by coprecipitation of iron salts, followed by coating with a silica-
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thiol shell (Figure 4.12A). This coating notably improved the stability of the nanoparticles in 
PEGDMA solution while also providing functional thiol groups for direct crosslinking of the 
particles to the polymer backbone by free radical addition. The ferromagnetic precursor solution 
was used to fabricate magnetic microrods by UV-photolithography (Figure 4.12B). These 
microrods were grown with cardiomyocytes and shown to be nontoxic as no cell death was 
observed during 4 days in culture. During this time, cardiomyocytes formed attachments to the 
microrods, enabling remote force loading using a neodymium magnet (Figure 4.12C). Line scans 
were taken before and after loading through the SPION microrod (Figure 4.13A-B). Kymographs 
showed an increase in contractile displacement, as well as permitting measurements for the 
contractile rising and relaxation falling phases. Changes in contractile metrics due to SPION 
microrod loading was studied in 30 cells. As determined by an increase in contractile 
displacement, success rate for eliciting a response through SPION microrod loading was 
approximately 66.6% (20 out of 30 cells), though all experiments were included in the analysis. 
Contractile displacement was significantly different in cells following loading, increasing from 
1.88 µm to 2.17 µm (Figure 4.13C, p = 0.028). Beats frequency showed no difference before and 
after loading CMs, at 47.49 beats/minute and 46.69 beats/minute (Figure 4.13D). A change in 
contractile velocity was observed between the two conditions, increasing from 50.47 µm/s to 
59.48 µm/s following loading (Figure 4.13E, p = 0.046). No difference was seen in relaxation 
velocity before and after loading CMs, at 21.18 µm/s and 22.75 µm/s (Figure 4.13F). 
 
4.4 Discussion 
While initially presented as a tissue engineering tool for delivery of mechanical cues, 
polymeric microrods can be adapted for a variety of therapeutic and research applications. 
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Microrods made of PEGDMA and HA can be used as drug carriers for drug delivery or as a 
secondary arm of therapy in addition to the previously described microtopography-based 
mechanisms90,92,93,114. Doroudian et al fabricated PEGDMA microrods that released mechano-
growth factor (MGF) peptide over 14 days to stimulate migration of human mesenchymal stem 
cells (hMSCs) and protect neonatal rat ventricular myocytes (NRVMs) from hypoxia induced 
apoptosis147. PEGDMA microstructures were initially selected for these investigations because it 
is commercially available and its crosslinking density can be easily tuned, allowing for facile 
optimization of release kinetics. In contrast, HA microrods have a very large mesh network at all 
practical concentrations and are not suitable for delivery of small molecules, releasing them 
almost instantaneously. Instead, HA microrods can be used for delivery of larger biologics, 
relying on enzyme mediated degradation to slowly release proteins or peptides entrapped in the 
polymer matrix. 
There are many benefits to using drug-loaded microrods to deliver therapeutic cargo. 
First, incorporation of small molecules into the PEGDMA matrix allows for tunable release 
kinetics. Increasing crosslinking density will lengthen the therapeutic timeframe while lower 
monomer concentrations may be ideal for when a high loading dose is required. This ease of 
tunability is crucial for using microrods in drug delivery applications because different diseases 
will require different drug release profiles. Further, encapsulation of the drug cargo within the 
polymer matrix may protect it from degradation until eluted from the microrod, enhancing the 
stability of the treatment. Interestingly, we also observed that the alanine-loaded microrods were 
able to improve cell viability to an equal or greater extent than high concentrations of free 
alanine. This suggests that there may be a local effect at play, where cells near the microrods will 
have access to high concentrations of drug. This is a major advantage in cases where it is only 
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necessary to have high local drug concentrations around a specific cell, such as in cell 
transplants, which would normally require much higher amounts of drug in a bolus dose.  
There are, however, many questions left to be answered regarding the use of microrods as 
drug delivery devices. One concern is the unknown residence time of these microrods in vivo. 
Therapies requiring multiple injections may result in accumulation of microrods in the tissue due 
to negligible degradation. Incorporation of degradable functional groups into the polymer 
backbone is a potential solution to this issue and has been investigated in bulk hydrogels148–152. 
Further, we have extensively shown that bare microrods have anti-fibrotic properties, but their 
effects on beta cells, chondrocytes and stem cells requires more investigation. This information 
is crucial to decoupling the effects of the therapeutic and the microtopography for a more 
thorough understanding of the therapeutic mechanisms of action. 
We attached a variety of molecules to the microrod surface to impart additional 
functionalities and further explore possible applications of this microrod technology. 
Presentation of DNA on cell surfaces has previously been demonstrated for temporary control of 
cell-cell interactions and microtissue organization153–155. Here, we show that this strategy can be 
adapted to transiently attach small molecules, proteins, nanoparticles, or cells onto the microrod 
via binding of complementary sequences. For a therapeutic application, beta cells can be 
transiently adhered to microrods loaded with alanine, creating a nutrient “backpack” to promote 
survival after transplantation. This approach can also be used for a variety of cell types and 
diseases, such as transplantation of iPSC-derived cardiomyocytes for heart failure therapy. 
A range of ligands can also be conjugated to the microrod surface to activate signaling 
pathways upon binding and induce changes in cellular phenotype. HepIII, a collagen IV 
fragment, was previously shown to increase vessel density within the infarct area of a rat MI 
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model136,145,146. Here, we demonstrate the successful attachment of HepIII to HA microrods and 
cultured them with HUVECs to increase proliferation. This functionality can improve the overall 
therapeutic efficacy of HA microrod therapy after MI by stimulating formation of a vascular bed 
to support intrinsic myocardial repair mechanisms, in addition to the previously established 
antifibrotic effects. 
Microrods are also a powerful tool for studying the effects of mechanical forces on cell 
behavior. Magnetic nanoparticles were previously incorporated into the microrod matrix and 
used to align the microrods in 3D for controlled growth of fibroblast and cardiomyocytes156. 
Additionally, magnetic microrods can also be used for applications in 3D imaging. In the present 
study, SPION loaded microrods are used as force actuators that are compatible with live-imaging 
to study the effect of discrete forces on cardiomyocyte response. A simple placement of an 
external neodymium magnet allowed accurate measurement of transverse loading on cardiac 
myocyte contractility using phase microscopy. The focal adhesions formed between the 
microrods and the CMs were strong enough to load and displace CMs when the external magnet 
was introduced. The displacement resulted in significant changes to the rate of rise in tension of 
the CMs.  
Previous attempts have been made using magnetically actuated micropost surfaces to 
provide forces along the underlying surface of a cell, but these do not mimic the type of three-
dimensional strain experienced by cells in vivo157,158. Additionally, many of these studies could 
not be imaged while the cell was mechanically deformed. Signals and remodeling were also 
studied after static strain or after bouts of exercise, but these were not live cell recordings111,159–
161. In the current experimental arrangement, the microrods provide load mainly in a transverse 
direction across the myocyte. Changing the position of the external magnet to the side of the 
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culture dish would pull the SPION microrods along the longitudinal axis of the CM that could 
allow for sarcomere length dependent studies at the single cell level, potentially recapitulating 
the Frank-Starling law of the heart162,163. 
 
4.5 Conclusion 
Collectively, these studies demonstrate the immense versatility of the microrod platform. 
We explored a wide range of chemical, biological and mechanical modifications that confer 
additional functionalities to the microrods, making them suitable for drug delivery, tissue 
engineering and basic research applications. While still in its infancy, this microstructural 
approach is a highly promising and fruitful technology for continued investigation, with many 
modifications and optimizations that have yet to be explored. 
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Figure 4.1. Alanine-loaded microrods improve pancreatic islet survival. (A) PEGDMA 
microrods were successfully fabricated in a range of monomer concentration. (B) Release of 
alanine from microrods with lower PEGDMA concentration had more rapid release of alanine 
over 4 days. (C) Brightfield image of primary pancreatic mouse islets cultured with 20% 
PEGDMA microrods containing alanine. (D) Islets cultured with alanine-loaded microrods had 
higher % survival compared to untreated islets, as well as compared to islets treated with free 
alanine. 
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Figure 4.2. Surface functionalization of PEGDMA microrods. (A) PEGDMA microrods 
doped with primary amine groups can be functionalized with small molecules by EDC/NHS 
crosslinking. (B,C) Increasing the amount of primary amine groups result in increased 
fluorescence of microrods when conjugated with FITC-NHS. 
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Figure 4.3. Presentation of DNA oligos onto a microrod surface. (A) Amine-doped 
PEGDMA microrods can be functionalized with DNA molecules and complexed with 
fluorescent oligos. (B) Increasing AEMA results in more DNA functionalization, as well as 
nonspecific adsorption, likely due to charge interactions. 
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Figure 4.4. NVP-AEW541 loaded microrods elute drug over 9 days. 
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Figure 4.5. NVP-AEW541 loaded microrods blunt the effect of IGF-1 treatment on matrix 
metalloproteinase expression in vitro. (A) Incubation with NVP-AEW541 loaded PEGDMA 
microrods reduces expression of MMP9 and (B) MMP13 in ATDC5 cells treated with IGF-1 
(black bar = control, grey bar = IGF-1 treated). 
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Figure 4.6. Microrods loaded with IGF-1R inhibitor prevent subchondral bone loss during 
PTOA. (A) Schematic of loading device for ACL rupture. The lower leg is placed between the 
upper and lower loading cups which are attached to the load actuator and load cell, respectively. 
A single 18N compression is applied. The resistance to the load is monitored by the attached 
computer, and the change in resistance documents the rupture of the ACL. This load did not 
result in fractures. (B) Vehicle or IGF-IR inhibitor loaded microrods were injected in to the 
injured knee one day after ACL rupture. The left knee of each mouse was used as a normal 
control. Samples were collected 2 weeks after injury. As determined by µCT, ACL rupture 
(ACL, open bars) decreased the trabecular bone volume (BV/TV) compared to control knees 
(Ctrl, grey bars), while microrods blunted these effects (ACL+M, solid bars). (C) ACL rupture 
increased trabecular space (Tb.Sp) compared to control. IGF-IR inhibitor loaded microrods 
(ACL/M, solid bars) attenuated this increase in Tb.Sp. Results are expressed as mean ± SD. *p < 
0.05 vs. non-injured knee. 
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Figure 4.7. IGF-1R inhibitor-loaded microrods remain in knee capsule two weeks after 
injection. Large arrowhead indicates broken ACL and small arrows indicate microrods. 
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Figure 4.8. IGF-1R inhibitor-loaded microrods blunt the effects induced by ACL rupture 
and attenuate OA development. (A-C) Immunohistochemistry (IHC) staining using a 
phosphorylated ERK (pERK) antibody shows increased pERK expression (brown) in the 
articular chondrocytes of the injured knee (B) compared to the normal knee (A). These effects 
were blunted in the IGF-IR inhibitor treated knee (C). (D-F) Safranin O/fast green (S/F) staining 
shows that osteophyte was observed in the injured knee (E) but not in the normal (D) or 
microrod treated (F) knees. (G-I) IHC staining using a PCNA antibody showed that ACL rupture 
induces PCNA positive cells (brown) in the injured knee (H) compared to the non-injured knee 
(A), but these effects were not observed in the microrod treated knee (I). (J-L) ACL rupture (K) 
induces VEGF production when compared to the non-injured knee (J). IGF-1R inhibitor 
microrod treatment (L) blunted these effects. Black arrows indicate osteophyte, red arrow 
indicates abnormal vasculature in the cartilage. Scale bars = 50 µm (A-C), 200 µm (D-F) and 50 
µm (G-L).   
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Figure 4.9. IGF-1R inhibitor loaded microrods block MMP-13 production induced by ACL 
rupture. Immunohistochemistry using an MMP-13 antibody showed that compared with the 
non-injured knee (A), injury (B) induced MMP-13 production (brown). Treatment of the injured 
knee with IGF-1R inhibitor-loaded microrods (C) blunts the production of MMP-13. Pictures to 
the right are high magnification (scale bars = 50 µm) of the framed areas of the pictures on the 
left (scale bars = 100 µm). 
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Figure 4.10. HA microrods can be functionalized with amine-containing compounds via 
EDC/NHS coupling. (A) Fluorescence imaging confirms successful conjugation of HA 
microrods with a fluorescein-labeled HepIII peptide via EDC/NHS carbodiimide coupling. (B) 
Spectroscopy was used to quantify the amount of HepIII-FITC on the microrods and indicate 46 
µg of peptide per 100,000 microrods with limited nonspecific adsorption. Scale bars = 100 µm. 
The data are presented as the mean ± SD (n = 3). **p < 0.01. 
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Figure 4.11. HepIII microrods increase endothelial cell proliferation. Treatment of human 
umbilical vein endothelial cells (HUVECs) with HepIII-conjugated HA microrods increases 
proliferation rates compared to bare HA microrods and PBS controls. The data are presented as 
the mean ± SD (n = 3). *p < 0.05. 
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Figure 4.12. Development of ferromagnetic microrods for remote application of force on 
cardiomyocytes. (A) Fabrication scheme of PEGDMA microrods loaded with silica-thiol coated 
magnetic nanoparticles. (B) SPION-loaded microrods maintain magnetic properties and are 
rapidly attracted to a neodymium magnet. (C) Schematic of experimental setup, in which CMs 
are cultured with SPION microrods and form focal adhesions on them. An external neodymium 
magnet is then brought above the dish to provide load. 
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Figure 4.13. Cardiomyocyte cultured with magnetic microrods to study the effect of acute 
load on contractility. (A) Representative bright field image of line scan taken through cell 
interior. N indicates cell nucleus Scale bar: 20 µm. (B) Line scan kymographs before and after 
addition of magnet to provide load. Contractile velocities are obtained by measuring 
displacement and time of linear portion of contraction or relaxation and taking the slope. (C) 
Contractile displacement of myocytes increases with load, p = 0.028. (D) Beat frequency is 
unchanged following load from SPION microrods. (E) Contractile velocity increases with load, p 
= 0.046. (F) Relaxation velocity is unchanged following load from SPION microrods. 
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Chapter 5 – Near-Infrared Hydrogel-Nanosensor Composites for Real-Time Detection of 
Blood Analytes 
 
5.1. Introduction 
Chronic cardiovascular diseases are a daunting health challenge, costing the American 
healthcare system over 30 billion dollars annually164. This spending is expected to dramatically 
increase each year due to an aging patient population that continues to grow larger in the wake of 
improved diagnosis and treatment in the acute setting1. Currently, management of chronic heart 
failure (CHF) consists of periodic visits to primary care or specialized centers to obtain snapshots 
of disease progression followed by appropriate treatment2,165. Despite attentive care, an alarming 
number of adverse events still occur between visits, resulting in hospitalization of the patient, 
reduced quality of life and increased healthcare costs166–169. It is therefore necessary to change 
our approach in treating chronic diseases and develop technologies that allow patients to 
continuously monitor and control the progression of their disease state. 
In recent decades, there has been a push towards point-of-care testing for the self-
management chronic diseases165,170. The ability to monitor total health state from the bedside 
would inform patients and healthcare providers with greater frequency on the progression of 
chronic disease or the onset of additional comorbidities. This allows for more timely 
interventions and improve patient quality of life. It has been demonstrated that several blood 
metabolites correlate with unfavorable cardiovascular outcomes171–173. For example, high levels 
of lactate are indicative of low oxidative capacity and is predictive of CHF and HF-related 
mortality171,174. Similarly, monitoring of blood glucose levels facilitate the detection of diabetes, 
a major risk factor and comorbidity of cardiovascular disease175–178. The ability to accurately and 
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frequently measure these metabolites would help notify individuals when expert interventions 
are required, limiting the incidence of adverse events and improving patient quality of life. 
The most common of point-of-care tests are finger-prick blood tests, which utilize 
discrete blood samples that are analyzed ex vivo by a portable device. This allows patients to 
obtain a snapshot of their current health state in the convenience and comforts of their own 
home. Low patient compliance, however, significantly impairs the effectiveness of these tests, 
demanding alternatives for self-management179,180. Alternatively, implantable electrochemical 
sensors have been developed to continuously monitor blood analyte levels through percutaneous 
electrodes181–184. Benefits of this strategy include reduced responsibility from the patient to 
conduct discrete blood tests and the ability to detect major fluctuations throughout the day. 
However, the insertion of these electrodes causes undesired tissue trauma and carry a high risk 
for infection, resulting in a substantial immune response and eventual fibrotic encapsulation. In 
turn, the sensitivity of these sensors are severely compromised after implantation and require 
recalibration or replacement every 7-10 days184–186. Despite significant efforts to improve the 
sensitivity and durability of implantable sensors, there are few effective options for long-term, 
continuous metabolite sensing today. 
The development of a fully implantable, tissue-integrating sensor that can rapidly and 
reliably detect substrates in the physiological range would be a major advancement for 
continuous monitoring of chronic cardiovascular diseases. Here, we present the development of 
three hydrogel-nanoparticle composite sensors for the detection of oxygen, glucose and lactate. 
The use of a composite material allows us to independently optimize the mechanical and 
biochemical properties of the scaffold component and the responsiveness and specificity of the 
sensor component to create an optimal subcutaneous sensor. Furthermore, incorporation of 
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multiple nanoparticle sensors within one tissue-integrating hydrogel scaffold would generate a 
simple, personalized device for total health sensing. 
 
5.2 Materials and Methods 
5.2.1 Materials 
 Tetraethylene glycol dimethacrylate (TEGDMA), 2-hydroxyethyl methacrylate (HEMA), 
N-dimethylacrylamide (DMA), poly(methyl methacrylate) (PMMA) microparticles, 1-
Hydroxybenzotriazole hydrate (HOBt), ascorbate oxidase (AOx), o-dianisidine dihydrochloride, 
sodium L-lactate, horseradish peroxidase, sodium alginate, calcium carbonate, and glucono-δ-
lactone were purchased from Sigma Aldrich (St. Louis, MO). 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (NHSS), 
and L-ascorbic acid were purchased from Thermo-Fisher Scientific (Waltham, MA). Calcium 
chloride was purchased from bioWORLD (Dublin, OH). 100 nm amine-terminated silica 
nanoparticles were purchased from Nanocomposix, Inc (San Diego, CA). Lactate oxidase from 
Aerococcis viridans was purchased from A.G. Scientific (San Diego, CA). VA044 thermal 
initiator was purchased from Wako Chemicals USA, Inc (Richmond, VA). Acid-terminated 
palladium benzoporphyrin (Pd-BP), palladium benzoporphyrin methacrylate (Pd-BPMA), 
viologen boronic acid, and IRDye680 were donated by PROFUSA, Inc (South San Francisco, 
CA). 
 
5.2.2 Preparation of microporous HEMA:DMA hydrogels 
 Hydrogel scaffolds were fabricated utilizing previously described techniques187,188. 
Briefly, a 3 mm teflon spacer was sandwiched between two glass slides and used as a mold for 
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hydrogel polymerization. A prepolymer solution consisting of 50% monomer solution, 20% 
dimethyl sulfoxide (DMSO), 2% TEGDMA crosslinker, VA044 thermal initiator (10 mg/mL), 
and water/nanoparticle solution/free dye solution was prepared. The monomer solutions 
consisted of either pure HEMA or a 50:50 mixture of HEMA and DMA. The prepolymer 
solution was injected into the prepared mold and incubated at 37 °C for at least 4 hours. The 
crosslinked hydrogel was gently removed from the mold and allowed to swell in PBS. 
In order to form hydrogel scaffolds with interconnected micropores, PMMA 
microparticles were packed into the assembly described above and sintered to form a bead cake. 
Prepolymer solution was then injected and crosslinked as described above to form a hydrogel 
with interconnected PMMA beads. The PMMA beads were leached out by incubation in acetone, 
leaving behind a hydrogel with interconnected micropores. 
 
5.2.3 Synthesis and characterization of oxygen nanosensors 
 An acid-terminated palladium (II) benzoporphyrin (Pd-BP acid) was custom synthesized 
and donated by PROFUSA, Inc. Pd-BP acid was attached to amine-terminated silica 
nanoparticles using EDC/HOBt crosslinking chemistry. Pd-BP acid was dissolved in DMSO at 2 
mM and activated with EDC and HOBt for 30 minutes. The final concentrations were 1 mM, 10 
mM and 20 mM, respectively. This solution was added to aminated silica nanoparticles in 100 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 8.0) and allowed 
to react overnight on a shaker. Conjugated nanoparticles were centrifuged, washed thrice into 
HEPES buffer and stored until further use. 
Absorbance spectra were obtained in order to account for any shifts in peak excitation 
and emission wavelengths of the Pd-BP dye after conjugation to a nanoparticle. Pd-BP 
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nanoparticles were assayed for oxygen sensitivity by fluorescence in a plate reader format. 
Solutions of free Pd-BP, blank nanoparticles, and Pd-BP nanoparticles were degassed by N2 
stream for 15 minutes. The fluorescence of the nanoparticles was then measured over the course 
of 30 minutes to monitor reoxygenation due to gas exchange at the liquid-air interface. The 
solutions were then mixed thoroughly for complete reoxygenation to serve as baseline. 
 
5.2.4 Ratiometric oxygen sensor calibrations 
A methacrylate oxygen-insensitive dye (Cy5.5-MA) was prepared by reacting Cy5.5-
NHS with AEMA in equimolar concentrations. HEMA hydrogel sensors containing Cy5.5-MA 
and a methacrylated Pd-BP (Pd-BPMA) were fabricated as described above. Hydrogels were 
placed in a 96-well plate with 200 µL of PBS and degassed for 15 minutes by nitrogen stream. 
The fluorescence of all dyes was measured over the course of 30 minutes to monitor 
reoxygenation (excitation = 630 nm, emission = 665 nm, 800 nm). A calibrated NeoFox oxygen 
probe (Ocean Optics, Largo, FL) was used to track oxygen content of PBS that had also been 
deoxygenated for 15 minutes by N2 stream. Oxygen %/time was then compared to 
fluorescence/time to obtain a relationship curve for fluorescence and oxygen %. 
An ascorbate oxidase assay was developed to slowly deplete solution of oxygen for 
calibrations in a controlled manner. For these assays, hydrogel sensors containing Pd-BPMA and 
an oxygen-insensitive reference dye were donated by PROFUSA, Inc. A solution of ascorbate 
oxidase (2.5 U/mL) was prepared in PBS and allowed to equilibrate for 20 minutes. For plate 
reader calibrations, hydrogels were placed into a 96-well plate with 200 µL of ascorbate oxidase. 
To this, 10 µL of 10 mM ascorbate was added and the fluorescence was measured for 30 minutes 
(excitation = 630 nm, emission = 700 nm, 800 nm). Addition of ascorbate was repeated until 0% 
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oxygen was achieved. Similarly, a NeoFox oxygen probe was used to measure equilibrium 
oxygen content in solutions of ascorbate oxidase for each addition of ascorbate. These 
calibrations were repeated with an in vivo imaging system (IVIS) to measure oxygen tension in 
mice. 
 
5.2.5 Synthesis of glucose nanosensors 
Glucose nanosensors were synthesized using procedures similar to the oxygen sensors. 
An acid-terminated near-infrared wavelength fluorescent dye (IRDye680) and a viologen-based 
boronic acid (VBA) quencher were custom synthesized and donated by PROFUSA, Inc. Both 
compounds were attached to aminated silica nanoparticles in a range of concentrations using 
EDC/NHSS crosslinking chemistry. VBA and IRDye680 were dissolved in DMSO in a range of 
concentrations and activated with a 10-fold excess of EDC and 20-fold excess of NHSS for 30 
minutes. This solution was added to 10 mg/mL of aminated silica nanoparticles in 100 mM 
HEPES buffer (pH 8.0) and allowed to react overnight on a shaker. Conjugated nanoparticles 
were centrifuged, washed thrice into HEPES buffer and stored until further use. Absorbance 
spectra were obtained in order to account for any shifts in peak excitation and emission 
wavelengths of IRDye680 after conjugation to a nanoparticle. 
 
5.2.6 Quantification of IRDye680 and VBA on glucose nanosensors 
IRDye680 content on nanoparticles was quantified by absorbance at 680nm and 
subtracting baseline absorbance from blank nanoparticles. A degradation assay was developed to 
determine VBA content on the nanosensors. 200 µL of glucose nanosensors and standard 
solutions of free VBA were treated with 100 µL of 50 mM sodium hydroxide and incubated for 5 
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minutes. The absorbance of the glucose nanosensor sample was measured at 405 nm and 
compared to the standard curve to calculate VBA content.  
 
5.2.7 Characterization of glucose sensitivity 
To test the optical response of the nanosensors, samples were placed in a 96-well plate 
and challenged with gradual additions of glucose. Fluorescence was measured (excitation = 680 
nm, emission = 710 nm) for 10 minutes before any glucose addition to obtain baseline 
fluorescence readings. The concentration of glucose was increased to 50 mg/dL by addition of 
concentrated glucose (20 mg/mL) and the fluorescence was measured continuously until the 
signal stabilized. This process was repeated several times to reach 100 mg/dL, 200 mg/dL and 
600 mg/dL. Glucose sensitivity was reported as a ratio of intensity at 200 mg/dL over intensity at 
50 mg/dL.  
 
5.2.8 Determination of lactate oxidase activity 
Lactate oxidase activity was measured by a coupled enzyme assay. A reaction mix 
containing o-dianisidine dihydrochloride (0.0535 mg/mL), sodium L-lactate (16.611 mg/mL), 
and horseradish peroxidase (2 U/mL) were prepared in 80 mM sodium acetate buffer, pH 5.1. 
200 µL of this reaction mix was placed into a 96-well plate and lactate oxidase or lactate oxidase 
nanoparticles (LoxNP) were added. Immediately after addition, absorbance readings were taken 
at 449 nm to track the rate of conversion of lactate to pyruvate. The slope during the first minute 
was calculated and presented as OD/min as a measure of lactate oxidase activity. 
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5.2.9 Assessment of lactate oxidase stability 
Lactate oxidase stability and activity was assessed after being exposed to a variety of 
environmental conditions, including heat, UV exposure, pH levels to optimize chemical 
conjugation strategy. After these challenges, samples were assessed for enzymatic activity per 
the o-dianisidine assay mentioned above (5.2.8). 
 
5.2.10 Synthesis of lactate nanosensors 
Lactate nanosensors were prepared in a similar fashion to the previous sensors 
mentioned. Lactate oxidase in a range of concentration (5 U/mL to 1000 U/mL) was activated 
with a 10-fold molar excess of EDC and 20-fold molar excess of NHSS in phosphate buffer (pH 
5.5) for 30 minutes. To this solution, a 1.5-fold volume of 10 mg/mL amine-terminated silica 
nanoparticles in 100 mM HEPES buffer (pH 11) containing 0.1% polyethylene glycol (MW = 
5000 Da) was added and reacted for 4 hours while stirring. The particles were washed eight 
times by centrifugation to eliminate all traces of free lactate oxidase. 
 
5.2.11 Preparation of alginate hydrogels 
Alginate hydrogels were prepared using an internal gelation method189,190. Alginate was 
dissolved in water at a 4% w/v concentration and filtered through a 0.22 µm filter. Lactate 
oxidase nanoparticles and calcium carbonate were added to the filtered alginate solution and 
thoroughly mixed. Glucono-δ-lactone was then added and thoroughly mixed to initiate gelation. 
The final concentrations of lactate oxidase nanoparticles, calcium carbonate and glucono-δ-
lactone in the hydrogel solution were 8 mg/mL, 4.2 mg/mL, and 7.5 mg/mL, respectively. The 
final concentration of alginate was 1.5% w/v or 2.0 w/v depending on the formulation. The 
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solution was immediately injected into a mold to crosslink overnight. Once fully set, the alginate 
hydrogel was removed from the mold and stored in TRIS buffer containing 90 mg/mL calcium 
chloride.  
 
5.3 Results 
5.3.1 Synthesis of oxygen nanosensors 
A carboxylic acid-modified palladium benzoporphyrin was activated with EDC/HOBt 
and successfully attached to amine-coated silica nanoparticles (Figure 5.1A-C). Nanoparticles 
that were reacted with EDC/HOBt activated Pd-BP were bright green after purification, 
compared to nanoparticles that were reacted with control Pd-BP. Absorbance spectra of 
conjugated nanoparticles, control particles and free Pd-BP showed that the absorbance peaks of 
Pd-BP did not shift upon conjugation to a particle (Figure 5.1D). Pd-BP nanoparticles also 
maintained an emission peak at 800 nm (Figure 5.1E). A solution of Pd-BP nanoparticles was 
degassed by nitrogen stream and allowed to reoxygenate over time.  There was a 10-fold 
difference in fluorescence between nanoparticles in the absence of O2 compared to fully 
oxygenated particles (Figure 5.1F). 
 
5.3.2 Calibration of ratiometric fluorescence to oxygen tension 
In order to optimize this system for detection of oxygen in vivo, a ratiometric sensor was 
developed using a methacrylated Pd-BP (Pd-BPMA) and a methacrylated Cy5.5 (Cy5.5-MA). 
HEMA hydrogels were fabricated in a range of Pd-BPMA concentrations and a fixed 
concentration of Cy5.5-MA. For all hydrogel samples, there was no response of the Cy5.5 dye 
(665 nm) to variations in oxygen (Figure 5.2A). Increasing Pd-BPMA concentration increased 
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O2 response, with less improvement after 1 mM Pd-BPMA. The fluorescence ratio (I800/I665) was 
calculated and plotted over time to be used as a measure of oxygen level (Figure 5.2B). 
Additionally, the reoxygenation kinetics of an oxygen-depleted solution was measured over time 
using a NeoFox oxygen probe (Figure 5.2C). This was used to calibrate the oxygen sensors and 
give a relationship between fluorescence ratio, which can be measured in vivo, to oxygen tension 
(Figure 5.2D). 
An ascorbate oxidase-based assay was developed to more precisely modulate oxygen 
levels for O2 sensor calibrations. In the presence of ascorbate oxidase, ascorbate is converted to 
dehydroascorbate, consuming oxygen in the process. We found that adding specific 
concentrations of ascorbate to an ascorbate oxidase solution quickly depletes oxygen in the 
solution, with increasing ascorbate leading to linear decreases in oxygen tension to a minimum 
of 0% at 0.75 mM ascorbate (Figure 5.3A). Similarly, addition of ascorbate increases 
fluorescence of Pd-BPMA as a result of reduced oxygen tension (Figure 5.3B-C). These 
relationships were used to calibrate the fluorescence ratio of hydrogel sensors to oxygen tension 
(Figure 5.3D). We repeated these calibrations within an in vitro imaging system (IVIS) and were 
able to determine oxygen tension within free hydrogel sensors, sensors encapsulated in 
polycaprolactone thin-film devices, and sensors implanted into a mouse (Figure 5.4D).  
 
5.3.3 Optimization of glucose sensitivity 
A two-component sensing system consisting of a near infrared dye (IRDye680) and a 
boronic acid-based viologen (VBA) quencher was used to detect glucose (Figure 5.5A). In the 
absence of glucose, there is electrostatic association of VBA with the fluorescent dye, leading to 
reduced fluorescence. Upon binding to glucose, VBA is neutralized and has diminished 
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quenching efficiency. It has been previously established that boronic acid positioning plays an 
important role in determining quenching activity. It is therefore likely that total IRDye680 and 
VBA concentration, and thereby molecular proximity, would be critical for optimization of a 
glucose sensor. We fabricated HEMA-based hydrogels containing IRDye680 and VBA in a fixed 
1:10 ratio at varying total concentrations to examine this dependence (Figure 5.5B). When 
challenged with glucose, hydrogel sensors with higher concentrations of IRDye680 and VBA 
have better sensitivity to glucose, while those with less than 5 mM VBA and 0.5 mM IRDye680 
have limited sensitivity that was more similar to drift than stepwise increases in fluorescence 
(Figure 5.5B-C). 
This high proximity position of dye and quencher can be reproduced on a nanoparticle, 
where each component is concentrated on the nanoparticle surface. We first developed an assay 
to determine the concentration of VBA, which is normally colorless, on a nanoparticle. Upon 
treatment with a strong base, the viologen degrades and obtains an absorbance peak at 400 nm 
(Figure 5.6A). A range of concentrations of VBA were treated with increasing concentrations of 
sodium hydroxide to determine the degradation kinetics of VBA. Interesting, we find that 100 
mM NaOH is required to fully degrade VBA in the detectable range (Figure 5.6B). We 
compared standard curves generated with each concentration of NaOH and found that 10 mM 
NaOH to 100 mM NaOH generated the same standard curves (Figure 5.6C). 
We proceeded to conjugate these components onto an amine-coated silica nanoparticle. 
Both VBA and IRDye680 were activated by EDC/NHS chemistry and attached to the 
nanoparticle under basic conditions (Figure 5.7A). The ratio of VBA and IRDye680 was varied 
from 1:15 to 1:50 to optimize glucose sensitivity of the nanoparticles. When VBA and IRDye680 
were not treated with EDC/NHS, silica nanoparticles exhibited no conjugation of quencher and 
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dye compared to particles treated with EDC/NHS activated VBA and IRDye680, which appeared 
bright blue (Figure 5.7B). When challenged with glucose, all nanoparticles exhibited sensitivity 
to glucose, with 1:50 ratio of IRDye680:VBA having the greatest glucose modulation (Figure 
5.7C-D). When these sensors were treated with control solution, sensors with a 1:15 ratio of 
IRDye680:VBA had some drift in fluorescence while 1:50 sensors had little to no response. 
 
5.3.4 Lactate sensitivity and stability 
 An enzyme-based nanoparticle was developed for the detection of lactate. Compared to 
analyte-responsive fluorophores, enzyme-based sensing systems benefit from short response 
times and high specificity. However, enzymes can be more sensitive to degradation or 
denaturing, leading to reduced activity. Our goal was to attach lactate oxidase onto a silica 
nanoparticle by formation of a stable amide bond. We initially tested the sensitivity of lactate 
oxidase to a variety of buffer conditions that were used during EDC/NHS coupling. Lactate 
oxidase maintained its activity in MES and HEPES buffer relative to activity in PBS (Figure 
5.8A). Interesting, lactate oxidase had slightly higher activity in HEPES buffer (p < 0.001), 
suggesting that storage in HEPES buffer may provide additional stability. 
 We then investigated the conjugation of lactate oxidase through formation of amide 
bonds via lysine residues. Sodium acetate was activated by EDC/NHSS and reacted with lactate 
oxidase. Interestingly, conjugation via lysine residues leads to significantly reduced activity 
compared to both control (MES buffer) and sodium acetate without EDC/NHSS activation 
(Figure 5.8B, p < 0.0001). This suggests that conjugation by lysines causes occupation of key 
reactive sites on the enzyme, leading to significantly reduced enzymatic activity. Therefore, we 
investigated conjugation of lactate oxidase to amine-coated silica nanoparticles by the C-
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terminus of the enzyme. Lactate oxidase was activated with EDC/NHSS and attached to silica 
nanoparticles as previously described (Figure 5.9A). The lactate oxidase nanoparticle sensors 
maintained enzymatic activity, suggesting limited loss in activity after conjugation (Figure 5.9B). 
In order to maximize enzymatic activity of the nanosensors, silica nanoparticles were conjugated 
with increasing concentrations of lactate oxidase. Enzymatic activity of nanoparticles was 
maximized (2000 mU/mg of particle) in reactions with 500 U/mL of EDC/NHSS activated 
lactate oxidase, after which there was a decline due to aggregation of enzyme (Figure 5.9C). 
Stability of these nanosensors at physiological temperature was assessed and found to be 
unaffected (Figure 5.9D). By contrast, challenge of nanosensors with lactate resulted in gradual 
reduction of activity, likely due to the production of reactive peroxidases during the enzymatic 
conversion of lactate to pyruvate (Figure 5.9E). 
 These nanoparticles were incorporated into a HEMA scaffold and found to have 
significantly reduced enzymatic activity (Figure 5.10A). While lactate oxidase is stable to UV 
exposure and incubation at 37C, the presence of thermal and photo-initiators that result in the 
formation of free radicals causes substantial degradation of the enzyme (Figure 5.10B-C). 
Milder crosslinking strategies were therefore to incorporate lactate nanosensors into a 
hydrogel scaffold without affecting enzymatic activity. Alginate hydrogel scaffolds were 
fabricated by an internal gelation method using calcium carbonate and a weak acid189,190. This 
enabled incorporation of nanosensors, as well as other sensing chemistries, without the use of 
free radicals or covalent crosslinking (Figure 5.10D). When challenged with lactate, 1.5% w/v 
and 2.0% w/v alginate hydrogels containing lactate oxidase nanosensors had considerable 
enzymatic activity, as compared to those made with HEMA via free radical polymerization 
(Figure 5.10E)  
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5.4 Discussion 
The ability to continuously detect blood oxygen, glucose and lactate presents exciting 
opportunities for heart failure diagnosis. Although a variety of specific biomarkers are associated 
with myocardial infarction and heart failure, these substrates typically consist of proteins or 
peptides that are difficult to continuously measure via an implantable sensor25,173,191,192. By 
contrast, detection of small molecule targets, such as oxygen, glucose and lactate, have been 
frequently reported in the form of optical and electrochemical sensors, and can be applied 
towards risk assessment of cardiovascular disease171,174,193–195. For example, high blood lactate 
indicate hypoxemia and can warn patients and medical providers of compromised cardiac 
function and output174. Elevated blood glucose levels can inform patients on the development of 
diabetes, a major comorbidity of cardiovascular disease that increases the risk for MI175–178. 
Conversely, individuals who have experienced MI are also more likely to develop diabetes, 
which exacerbates the progression and risk for total heart failure196,197. 
 In this study, we describe the synthesis of three novel nanoparticle sensors for continuous 
measurement of blood oxygen, glucose and lactate levels. These sensors utilize near-infrared 
dyes in combination with a range of chemistries to modulate fluorescence as a function of 
metabolite concentration. Additionally, these dyes can be excited and detected through skin with 
minimal loss in signal due to the exceptional penetration depth of near infrared wavelengths. 
 The ideal optical sensor would rapidly integrate with the host tissue, avoid fibrotic 
encapsulation, and maintain sensitivity and specificity for extended periods of time. Our 
nanoparticle sensors were embedded into a microporous hydrogel scaffold that supports 
ingrowth of blood vessels to promote intimate integration with the host tissue. This design 
reduces the diffusion distance between the vasculature and the nanosensors for rapid detection. 
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Additionally, our nanosensors were independently optimized for sensitivity without affecting the 
properties of the hydrogel matrix. This separation of function also enables incorporation of 
multiple different types of nanosensors within the same scaffold for simultaneous monitoring of 
multiple analytes. 
For the oxygen sensor, we utilized a fluorescent palladium benzoporphyrin (Pd-BP) that 
coordinates with oxygen similarly to the heme functional group (Figure 5.1A). The emission 
intensity of the phosphor is very low at ambient conditions as a result of collisional quenching. 
When oxygen levels are low, there is less energy transfer from the phosphor to the oxygen 
molecules, leading to increased fluorescence intensities187,188,198. This relationship between 
fluorescence and oxygen concentration can be described by the following Stern-Volmer 
equation, where I0f is the intensity without quencher, If is the intensity in the presence of 
quencher with quencher coefficient kq, τ0 is the emissive lifetime and [Q] is the concentration of 
the quencher. 
𝐼𝐼0𝑓𝑓
𝐼𝐼𝑓𝑓
= 1 + 𝑘𝑘𝑞𝑞𝜏𝜏0 ∙ [𝑄𝑄] 
Methacrylated derivatives of this benzoporphyrin have been utilized in combination with 
hydrogel scaffolds to fabricate oxygen sensors for continuous tracking of tissue hypoxia in rats, 
pigs and humans198,199. These sensors utilize emission lifetimes as an output for oxygen tension. 
In our study, we utilize fluorescence intensity as an output, requiring additional calibrations. As 
shown in Figure 5.2B, we demonstrate that responsiveness of Pd-BP fluorescence to time after 
deoxygenation, which can be correlated to absolute oxygen levels. This was assessed more 
rigorously through an ascorbate oxidase assay that was used to control oxygen tension of a 
solution (Figure 5.3). In order to use these sensors in vivo, it is necessary to develop a dual-dye 
system to account for fluctuations in baseline fluorescence. An oxygen-insensitive near-IR dye 
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was utilized for ratiometric sensing. A ratio between the oxygen-sensitive dye and the oxygen-
insensitive dye could be used and prevent ambiguities due to loss in signal due to tissue depth. 
We demonstrate that fluorescence ratio can also be used as a measure of oxygen tension in vitro 
as well as in vivo (Figure 5.2D, Figure 5.3D, Figure 5.4).  
We conjugated an acid-modified derivative of this benzoporpyrin to silica nanoparticles 
in order to generate oxygen nanosensors that have a ten-fold increase in fluorescence at low 
oxygen compared to ambient conditions. This is comparable to the aforementioned homogeneous 
sensors where the dye was directly conjugated to the polymer matrix199. With these nanosensors, 
we are therefore able to maintain the oxygen sensitivity while being able to change the polymer 
matrix to accommodate other functionalities – such as reducing crosslinking density to enable 
more rapid diffusion of analytes. 
 The ability to localize the sensing chemistries onto a nanoparticle surface was tantamount 
for the development of a glucose sensor. This novel optical sensing chemistry utilized a near-IR 
wavelength dye that is modulated by a nearby quencher molecule. This quencher molecule is 
responsive to glucose due to the inclusion of two boronic acid groups, which upon binding to 
diols, gains additional negative charges that significantly hinders electron transfer between the 
quencher and fluorophore200–205. It has been previously demonstrated that positioning of the 
boronic acid moiety plays a large role in glucose modulation206. Therefore, it is likely that the 
sensitivity of a hydrogel scaffold consisting of these components would heavily depend on 
proximity of the dye and quencher. 
We hypothesized that the distance between the fluorophore and the quencher could be 
tuned by adjusting their total concentrations within the hydrogel scaffold, allowing for 
optimization of sensitivity. This was confirmed through generation of a library of sensors with 
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both IRDye680 and VBA covalently incorporated into the hydrogel network. Our results 
indicated that with a fixed ratio of dye to quencher, increasing their absolute concentrations, and 
by extension, their proximity to each other, improved the sensitivity of these hydrogel scaffolds 
to glucose. Conjugation of these moieties to a nanoparticle surface allowed us to significantly 
reduce the distance between dye and quencher and increase sensitivity. We further optimized 
these glucose nanosensors by optimizing the ratio of dye to quencher. With minimal amounts of 
quencher, there is increased fluorescent signal due to limited fluorescence inhibition. However, 
there is also reduced glucose modulation due to a reduction of glucose responsive groups. By 
increasing the amount of quencher, there was greater glucose modulation that was accompanied 
by overall lower fluorescence values. This trend continued up to a 1:50 ratio of dye to quencher. 
For all ratios, there were no additional increases in fluorescence after 600 mg/dL of glucose, 
which exceeds the physiologically relevant range.  
 The final sensor utilized lactate oxidase for the detection of lactate. Enzymes are highly 
specific and have rapid response times, which are ideal for incorporation into a hydrogel sensor. 
While a multitude of enzyme-based sensors have been developed, the variable sensitivity and 
stability of different enzymes necessitate thorough optimization for applications in sensing. 
Glucose oxidase has been widely used for optical and electrochemical glucose monitoring with 
great success207–209. In contrast, most lactate oxidase-based biosensors have limited operational 
lifetimes and efficacy due to the marked instability of the enzyme210–212. We conducted several 
assays to assess the stability of lactate oxidase for fabrication of lactate nanosensors. Enzymes 
are particularly sensitive to pH, which spans a large range during our EDC/NHS coupling 
strategy. Lactate oxidase was stable when incubated in buffers ranging from pH 5.5 to pH 8.0. 
Activity assays were performed with small quantities of lactate oxidase in concentrated buffers 
105 
 
to account for the variable activity of lactate oxidase at different pH values. 
A major concern when immobilizing proteins onto surfaces is the potential to occupy key 
reactive sites on the protein. For example, immobilization of antibodies must be done away from 
the antigen binding site to retain affinity and specificity. When conjugated to a carboxylic-acid 
terminated nanoparticle, there was limited lactate oxidase activity, suggesting that specific lysine 
groups make up the enzyme active site. This was confirmed by conjugation of lactate oxidase to 
acetate-NHSS esters (Figure 5.8). Conjugation of the enzymes carboxylic acid groups to an 
amine-terminated nanoparticle results in retention of enzymatic activity (Figure 5.9). 
Unsurprisingly, this activity was increased when more enzyme was attached to the nanoparticle 
surface. After 500 U/mL of lactate oxidase, there was significant aggregation of the enzyme 
leading to reduced nanosensor yield, and activity. These nanosensors retained their activity when 
incubated at physiological temperature, but were sensitivity to lactate challenge. We suspect that 
this is due to the accumulation of hydrogen peroxides that are a byproduct of the conversion of 
lactate to pyruvate. Clearance of peroxides in vivo is anticipated to alleviate this problem. 
The sensitivity of proteins to UV irradiation and free radicals is also well appreciated. 
Our previous nanosensors were embedded into a poly(hydroxyethyl methacrylate) (pHEMA) 
hydrogel scaffold, which were crosslinked by free radical polymerization. While stable to UV 
exposure and physiological temperatures, the incorporation of free-radical initiators severely 
diminished the activity of lactate oxidase, necessitating alternative hydrogel scaffolds or 
crosslinking strategies. Alginate scaffolds can be gently crosslinked with calcium ions while 
preserving enzyme activity. Typically, alginate is immersed in a solution of calcium chloride to 
immediately crosslink the polymer. Here, we utilized an internal gelation method that is 
compatible with molds. This method utilizes water-insoluble calcium carbonate in combination 
106 
 
with a weak acid to slowly release calcium into the polymer network. This slowly gels the 
alginate and can be used in combination with microbeads to generate microporous hydrogel 
scaffolds. The activity of the lactate oxidase was maintained after incorporation into the. 
In order to use these for sensing in vivo, we propose to combine this enzyme-based sensor 
with the palladium benzoporphyrin described above. Conversion of lactate to pyruvate is 
accompanied by consumption of oxygen, which can therefore be used as a proxy for lactate 
concentration. Additional optimization is required to incorporate Pd-BP into the alginate 
scaffold, which lacks functional handles that can be crosslinked to the acid groups. The oxygen 
nanosensors described in this chapter can be incorporated with the lactate nanosensors to 
introduce both functionalities into the alginate matrix. The addition of catalase to consume 
evolved hydrogen peroxide and prevent enzyme degradation can also be investigated to improve 
the sensitivity and stability.  
 As a whole, these studies show that optical nanosensors are a promising for the detection 
of blood analytes relevant to cardiovascular disease. Despite successes in the optimization of 
sensitivity, the long-term stabilities of these materials have yet to be assessed. For clinically 
relevant applications, it is necessary to have continuous sensors that can accurately measure and 
report blood analyte levels over a long period of time without loss in sensitivity or signal. When 
activity is lost or the sensor is deemed inaccurate, additional sensors can be implanted to replace 
them as these hydrogel sensors are biocompatible and can be fabricated with a small form factor. 
However, to accomplish the practical goal of reducing the frequency of doctor visits and putting 
the power of diagnostics into the patients’ hands, a lifespan of over three months is ideal. 
Additionally, while outside the scope of the present study, the development of instrumentation 
that can noninvasively excite and detect fluorescent signals from the nanosensors is also 
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necessary. A patient would ideally be able to read their blood analyte levels and be alerted to 
seek medical attention whenever certain threshold levels or patterns arise. By addressing these 
requirements, we can make self-diagnosis of heart disease more approachable to patients and 
empower them to take control of their disease state. 
 
5.5 Conclusion 
Nanoparticle sensors capable of detecting oxygen, glucose and lactate were synthesized 
and incorporated into tissue-integrating hydrogel scaffolds to form a composite implantable 
sensor. These materials utilize three unique sensing chemistries that are in the near-infrared 
spectrum and can therefore be detected through tissue. We systematically optimized each 
nanoparticle sensor to detect their respective analytes in the physiological range. Of these, the 
oxygen sensors were most rigorously calibrated for in vivo applications via ratiometric sensing. 
Future work will focus on calibrating the more complex glucose and lactate sensors for in vivo 
sensing, combining several nanoparticles sensors for multi-analyte sensing, and developing an 
optical reader to continuously excite and detect the fluorescent signals. Together, these 
advancements facilitate the development of personalized sensors capable of continuously 
monitoring crucial blood analytes, thereby enhancing our ability to manage chronic diseases. 
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Figure 5.1. Conjugation of silica nanoparticles with oxygen sensitive Pd-BP. (A) Chemical 
structure of Pd-BP. (B) Pd-BP was conjugated to silica nanoparticles by EDC/HOBt activation of 
the carboxylic acid groups followed by reaction with primary amines on the silica nanoparticle 
surface in basic conditions. (C) Images of purified silica nanoparticles show that treatment of Pd-
BP with EDC/HOBt results in successful conjugation to nanoparticles (right), compared to 
nanoparticles reacted with Pd-BP without EDC/HOBt (middle) and blank nanoparticles (left). 
(D) Pd-BP nanoparticles retain absorption peaks of free Pd-BP and have a distinguishable 
emission peak at 800nm (E). (F) Pd-BP nanoparticles show sensitivity to oxygenation with ~10-
fold difference in fluorescence (ex/em = 625/800). 
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Figure 5.2. Oxygen and fluorescence calibrations for ratiometric sensing. (A) Hydrogel 
sensors were fabricated with varying concentrations of O2 sensitive Pd-BP and 0.008 mM of 
Cy5.5, an O2 insensitive reference dye. Stern-volmer plots indicate dramatic loss in oxygen 
modulation below 1 mM (circles = 800 nm emission, triangles = 665 nm emission, blue = 0.75 
mM Pd-BP, red = 1 mM Pd-BP, green = 2 mM Pd-BP). (B) Intensity ratio of O2 sensitive Pd-BP 
to O2 insensitive Cy5.5 during oxygen modulation. (C) A NeoFox probe was used to measure the 
static reoxygenation kinetics of a deoxygenated solution over time. (D) Correlation curve of 
intensity ratio to oxygen content. 
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Figure 5.3. Development of ascorbate oxidase-based oxygen modulation. (A) Equilibrium 
oxygen content after addition of varying concentrations of ascorbate. (B) Representative 
fluorescence response of hydrogel sensors containing Pd-BP (emission = 800 nm) and a 
reference dye (emission = 700 nm) after addition of 1 mM ascorbate. (C) Equilibrium 
fluorescence ratio of Pd-BP to reference dye after addition of ascorbate. (D) Calibration of 
fluorescence ratio to oxygen content. 
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Figure 5.4. In vivo imaging of ratiometric optical sensors predict oxygen tension. (A) 
Equilibrium oxygen content after addition of varying concentrations of ascorbate. (B) 
Equilibrium fluorescence ratio of Pd-BP to reference dye after addition of ascorbate as measured 
by an in vivo imaging system (IVIS). (D) Representative IVIS images of free hydrogel sensors 
and sensors encapsulated within a polycaprolactone thin film device. (E) Representative IVIS 
images of hydrogel sensors implanted into a mouse model. 
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Figure 5.5. Two-component glucose sensing chemistry is concentration dependent. (A) A 
boronic-acid modified viologen molecule binds glucose to modulate the fluorescence of a near-
infrared dye (B) HEMA hydrogels containing IRDye680 and VBA at a fixed 10:1 ratio in a 
range of concentrations were challenged with additions of glucose (C) Intensity ratios of glucose 
sensitive hydrogels reveal that high total concentrations of IRDye680 and VBA are required for 
optimal sensing. 
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Figure 5.6. Detection of VBA quencher on glucose nanosensors. (A) Treatment of VBA with 
NaOH results in the appearance of an absorbance peak at 400 nm. (B) Absorbance of VBA at all 
concentrations plateau after treatment with 10 mM NaOH. (C) Standard curves of VBA are 
indistinguishable after treatment with at least 10 mM NaOH. 
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Figure 5.7. Optimization of glucose nanosensor fabrication. (A) Synthesis scheme of glucose 
nanosensors with IRDye680 and VBA quencher. (B) Comparison of silica nanoparticles reacted 
with IRDye680/VBA (left) and EDC/NHS activated IRDye680/VBA (right). (C) Glucose 
modulation of glucose nanosensors containing a range of IRDye680:VBA ratios show that higher 
ratios provide better modulation. (D) Table of intensity ratios for particles treated with glucose 
and particles treated with control (saline) indicate that higher IRDye680:VBA ratios have better 
modulation within physiological ranges (I200/I50) and limited drift in fluorescence upon addition 
of saline. 
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Figure 5.8. Stability of lactate oxidase in EDC/NHS coupling conditions. (A) Lactate oxidase 
activity is unaffected by incubation in buffers using during EDC/NHS coupling. (B) Conjugation 
of lactate oxidase to EDC/NHSS activated acetate results in the absence of enzymatic activity, 
likely due to the occupation of key reactive sites on the enzyme. The data are presented as the 
mean ± SD (n = 3). ****p < 0.0001. 
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Figure 5.9. Synthesis of lactate oxidase-coated silica nanoparticles for detection of lactate. 
(A) Reaction scheme of lactate oxidase conjugation involving EDC/NHS activation of the 
enzyme followed by attachment to amine-coated silica nanoparticles by amide bonds. (B) 
Enzymatic activity of lactate oxidase is maintained when attached to a nanoparticle. (C) 
Conjugation of silica nanoparticles with increasing concentrations of activated lactate oxidase 
reaches a maximum at around 500 U/mL, after which the particles begin to aggregate and yield 
significantly decreases. (D) Lactate oxidase nanoparticles are stable at 37C and do not lose 
activity over 6 days. (E) Lactate oxidase nanoparticles are sensitive to lactate challenge and have 
reduced activity over repeated lactate exposure. The data are presented as the mean ± SD (n = 3).  
 
117 
 
 
Figure 5.10. Incorporation of lactate oxidase nanoparticles in alginate hydrogels scaffolds 
maintains enzymatic activity. (A) Lactate oxidase nanoparticles lose enzymatic activity after 
incorporation into HEMA hydrogels (white circle = LOx hydrogel, white diamond = blank 
hydrogel, red = 0.125 mU/mL, green = 1.25 mU/mL, blue = water). (B,C) Lactate oxidase is 
stable at 37 °C and in the presence of UV light, but loses activity in the presence of thermal and 
photo-initiators. (D) Schematic of alginate hydrogel synthesis using internal gelation methods. 
(E) Activity of lactate oxidase is maintained after incorporation into the alginate hydrogel (blue = 
1.5% w/v alginate, red = 2% w/v alginate). The data are presented as the mean ± SD (n = 3). **p 
< 0.01, ****p < 0.0001. 
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Chapter 6 – Conclusion and Future Work 
Chronic heart failure is a complex and debilitating medical condition affecting more than 
26 million people worldwide213. While a multitude of therapeutic interventions have been 
developed to address the symptoms of CHF and improve patient quality of life, there is no 
effective therapy that treats the underlying complications of LV remodeling and 
reparative/interstitial fibrosis that lead to progressive deterioration of cardiac function. This is 
largely attributed to our incomplete understanding of the multifaceted processes involved in 
innate myocardial repair. For example, tissue scarring is a necessary response to acute injury that 
facilitates tissue recovery after trauma. In myocardial tissue, this physiological response becomes 
aberrant and pathological, leading to excessive synthesis of scar tissue and continuous tissue 
stiffening5,7,11,12. The mechanisms by which this happens has been extensively studied but 
effective interventions remain elusive. It has therefore become a large focus of heart failure 
research to target heart failure on a cellular level and elucidate the mechanisms myofibroblast 
transformation and phenotype to mitigate the aberrant responses that contribute to pathological 
fibrosis while allowing the beneficial aspects of rapid healing and recovery. In this dissertation, 
we presented novel research in the use of micro-engineered hydrogel materials for diagnostic and 
therapeutic applications for the management of heart failure. 
First, we developed bioresorbable hyaluronic acid-based microrods that deliver local 
biophysical and biochemical cues to fibroblasts and cardiomyocytes for the attenuation of 
cardiac fibrosis and preservation of cardiac function after MI. The mechanical properties and 
degradation behavior of these microrods were extensively characterized and optimized for 
applications in cardiac fibrosis. These microstructures were shown to interact closely with 
cardiac fibroblasts in vitro and in vivo, which resulted in downregulated expression of genes 
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characteristic of myofibroblast transformation, including αSMA and Col1A2, as well as TGFβ 
and Smad3, key factors in mechanotransduction. Further, there was a downregulation of matrix 
metalloproteinases involved in LV remodeling, suggesting beneficial effects beyond attenuation 
of fibrosis. All of these changes resulted in functional improvements in an in vivo model of MI. 
While fabrication of microrods with bioactive polymers conferred favorable chemical and 
therapeutic properties to this micromechanical approach, there is great promise in adding 
chemical functionality through surface functionalization or drug loading to fit a range of 
scientific and therapeutic applications. We were able to attach single-stranded DNA to the 
surface of PEGDMA microrods for cell delivery applications, as well as attach proangiogenic 
peptides to the HA microrods to improve endothelial cell growth and promote vascularization. 
Microrods were also loaded with small molecule drugs to treat osteoarthritis and amino acids to 
improve beta cell survival for the treatment of type-1 diabetes. Additionally, magnetic 
nanoparticles were incorporated into the microrods, enabling remote manipulation of 
cardiomyocytes to study the effect of mechanical load on cellular phenotype by imaging. 
Collectively, these studies illustrate the immense diversity of modifications that can be made to 
this microtopography-based approach to improve existing therapeutic strategies and address a 
multitude of diseases. 
Lastly, as with many chronic conditions, disease management is paramount to improving 
patient quality of life and increasing life expectancy. We synthesized a set of three optical 
nanosensors for the detection of oxygen, glucose and lactate. These nanosensors were 
incorporated into hydrogel scaffolds that can be implanted subcutaneously for continuous 
detection of these blood metabolites, which can be used to inform patients and healthcare 
providers of any changes in disease state for rapid and effective treatment.  
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In summary, this dissertation presents a broad set of technologies developed to address the 
chronic challenges of heart failure. While the material properties and therapeutic effects of the 
hyaluronic acid-based microrods have been thoroughly characterized, there remain unanswered 
questions regarding mechanism of action. The material effect of HA in myocardial infarction has 
been well appreciated in the presented experiments, as well as in the literature, but the biological 
mechanisms underlying the combination of HA with microtopography is still unclear. Future 
experiments will investigate the individual and synergistic roles of HA receptors and integrins on 
mechanotransduction that lead to the observed phenotypic changes in fibroblasts and 
cardiomyocytes. Furthermore, while the current HA microrod formulation was demonstrated to 
be effective in attenuating aberrant LV remodeling and preserving cardiac function, there remain 
opportunities to optimize stiffness or methacrylate percentage for improved therapeutic effects in 
the context of MI or for applications in other biological systems. Lastly, it will be critical to 
implant the optical nanosensors described in chapter 5 in an animal model to validate sensitivity, 
accuracy and stability. Together, these proposed studies will improve upon the technologies 
presented in this dissertation and enhance our currently limited capabilities in treating heart 
failure in a rapidly growing patient population. 
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